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Abstract 
Plasmodium falciparum is a protozoan parasite that causes a severe form of malaria, a 
mosquito-borne infectious disease in humans.  P. falciparum encodes a number of proteins to 
facilitate its life-cycle, including a type II heat shock protein 40 (Hsp40), Pfj2.  Pfj2 shows a 
degree of homology to human ERdj5, a resident protein of the endoplasmic reticulum (ER) 
that promotes protein quality control by facilitating the degradation of misfolded proteins.  
The overall aim of this study was to further understand the function of Pfj2 in the P. 
falciparum cell by characterising it biochemically.  A bioinformatic analysis of Pfj2 was 
carried out to enable the identification of a potential ER signal sequence and cleavage site.  
Furthermore, an analysis of Pfj2 protein sequence was performed to compare domain 
similarities and identities with typical type II Hsp40s namely, human ERdj5, S. cerevisiae 
Sis1, human Hsj1a and human DnaJB4.  The method used included the insertion of the 
codon-optimised coding sequence for the processed ER form of Pfj2 into the prokaryotic 
expression vector, pQE30, to enable overproduction of a histidine-tagged protein.  A 62 kDa 
His6-Pfj2 was successfully expressed in Escherichia coli and purified using denaturing nickel 
affinity chromatography.  ATPase assays were performed to determine the ability of His6-
Pfj2 to stimulate the chaperone activity of the ER Hsp70, also called immunoglobulin binding 
protein (BiP).  Initial studies were conducted on readily available mammalian His6-BiP as a 
control, which was shown to have an intrinsic activity of 12.07±3.92 nmolPi/min/mg.  His6-
Pfj2 did not stimulate the ATPase activity of mammalian His6-BiP, suggesting that it either 
could not act as a co-chaperone of mammalian His6-BiP (specificity), or it required a 
misfolded substrate in the system.  Therefore, ongoing studies are addressing the interaction 
of Pfj2 and misfolded substrates with P. falciparum BiP.  The results of these studies will 
further our understanding of a poorly-studied parasite chaperone that represents a potential 
drug target for development of novel strategies for the control of a serious human disease. 
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1.1. Malaria: A human health concern 
Malaria is a mosquito-borne infectious disease caused by obligate intracellular protozoan 
parasites of the genus Plasmodium.  Five Plasmodium species namely, P. falciparum, P. 
knowlesi, P. malariae, P. ovale and P. vivax are known to cause malaria in humans.  P. 
falciparum, accounts for the majority of the 800, 000 malaria-associated human fatality cases 
each year.  Most mortality cases are children under the age of five (World Health 
Organisation, 2012).   
Malaria is one of the major health challenges facing developing countries and is responsible 
for high mortality rate with over 90% of cases occurring in Sub-Saharan Africa (World 
Health Organisation, 2012).  Malaria is endemic mostly in the tropical and subtropical areas 
(Figure 1.1).  In addition to Africa, areas with prevalent malaria transmission rate include 
South and Southeast Asia and Central and South America highlighted in maroon.  The 
Middle East and the Caribbean, highlighted in pink, represents areas where malaria is largely 
eliminated while the remaining regions of the world, highlighted in green, are malaria-free 
areas.  Examples of malaria-endemic countries thus include Brazil, Columbia, Kenya, 
Nigeria, Thailand, and Vietnam. 
 
 
 
 
 
 
 
 
 
Figure 1.1:  The geographical distribution of malaria (Sabeti, 2008). Green: Malaria-free areas; 
Maroon: Malaria-transmission areas; Pink: Areas where malaria is largely eliminated.  
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1.1.1. History of malaria 
Malaria is an ancient disease that has been noted for over 4000 years.  References to malaria 
related symptoms were documented in Chinese medical writing from about 2700 BC (Cox, 
2010).  There were speculations for over 2500 years that malaria fevers were caused by ‘bad 
air’ rising from swamps from the Italian the word ‘mal’aria’ which means spoiled air (Reiter, 
2000).  Studies on malaria intensified after the discovery of the parasite in the blood of 
malaria infected patients by a French scientist, Alphonse Laveran (Laveran, 1881).  Ronald 
Ross, a British doctor, suggested that mosquito vectors are implicated in transmitting avian 
malaria (Ross, 1898).  Italian malariologists discovered that anopheline mosquito vectors are 
responsible for transmission of human malaria parasite (Celli, 1933). Our understanding that 
the malaria parasite develops in the human liver prior to entering the blood stream was 
elucidated by Henry Short and Cyril Garnham in 1948 (Cox, 2010).   
 
1.1.2. Symptoms of malaria 
Malaria infections symptoms mostly manifest as fever, chills and mild anaemia (reviewed in 
Beare, 2006).  Symptoms of high level of parasitemia, severe malaria, manifest with major 
signs of organ dysfunction including cerebral malaria, pulmonary edema and acute renal 
failure (Trampuz, 2003).  Young children and pregnant women in particular are at high risk 
for severe malaria (Desai, 2007).  A common manifestation of severe malaria in children 
includes seizures and hypoglycaemia whereas jaundice and renal failure are common in 
adults (White, 2004).  Older children and adults are able to develop partial immunity after 
repeated infections, and are therefore at low risk for severe malaria (Desai, 2007).  Although 
malaria can be treated and cured, many of the available antimalarial agents such as 
chloroquine are virtually ineffective due to the development of resistance by P. falciparum. 
(Guerin et al., 2002). 
 
1.1.3.  Malaria treatment 
Existing approaches towards malaria control are the use of insecticides and prevention of 
contact with anopheline mosquito using screens and insecticide-treated bed nets (World 
Health Organisation, 2012). Antimalarial drugs such as chloroquine, doxycycline and 
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mefloquine are available but are partially or completely ineffective due to resistance 
(Jacquerioz and Croft, 2009).  Uncontrolled use and poor quality drugs could also cause 
emergence of resistance (Guerin et al., 2002).  The availability of fake artesunate and 
mefloquine has been reported throughout Southeast Asia (Newton et al., 2001; Rozendaal, 
2001).  A notable exception to resistance is the new class of antimalaria agents, artemisinins, 
which are natural products developed in China in the 1960s (Gamo et al., 2010; Woodrow et 
al., 2005).  Artemisinins have rapid antiparasitic activity.  However, artemisinins have short 
half-lives, hence these drugs are administered in combination with a longer acting agent and 
combination therapy is also used to avoid development of drug resistance. Examples of 
efficacious artemisinin-based combination are artesunate-mefloquine, artemether-
lumefantrine and artesunate-amodiaquine (Gamo et al., 2010; Rosenthal, 2008).  The 
intravenous and intramuscular administration of quinine has been the standard therapy for 
severe cases of P. falciparum malaria for many years however it is associated with toxic 
effects such as reversible hearing loss and hypoglycaemia (White, 1983).  Nausea and 
vomiting are the common side effects relating to artemisinins, which could be as a result of 
acute malaria rather than the drug (Price et al., 1999).  Correct use of chemoprophylaxis such 
as clindamycin and pyrimethamine could aid to prevent malaria.  There is currently no 
available malaria vaccine.  Malaria control is limited by drug resistance, therefore, there is an 
urgent need for novel drug development and strategies to tackle this disease.  
 
1.2. The life cycle of P. falciparum 
The P. falciparum life cycle takes place in two different hosts namely, insect vector and 
human.  The genesis of the malaria parasite in the human host is as a result of inoculation of 
sporozoites into the bloodstream by an infected anopheline mosquito (Step 1) (Figure 1.2) 
(reviewed in Zuccala and Baum, 2011). The motile sporozoites within 14 days migrate to the 
liver invading the hepatocytes, and upon repeated replication, growth and transformation the 
hepatocytes rupture, releasing merozoites into the bloodstream (Step 2).  The merozoites 
invade the host erythrocytes and undergo cellular division within 48 hours causing the 
erythrocytes to burst (Step 3).  This asexual blood stage of the P. falciparum accounts for the 
clinical symptoms associated with malaria infection such as fever, anaemia and organ 
deterioration.  As the infection progresses, merozoites develop into gametocytes that are 
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taken up by feeding anopheline mosquito. Gametocytes mature into male and female 
gametes, sexual reproduction occurs and a zygote (ookinete) is formed (Step 4).  Further 
multiplication and development take place resulting in the formation of infectious sporozoites 
that migrate to the salivary glands of the mosquito and are injected into a new host (Step 5) 
(Chang et al., 2008; Cox, 2010). 
 
 
 
 
 
 
 
  
Figure 1.2:  Schematic representation of P. falciparum life cycle (Adapted from Zuccala and 
Baum, 2011).  (1) : Injection of sporozoites by infectious anopheline mosquito; (2) : Exoerythrocytic 
hepatic invasion by sporozoites resulting in merozoite production; (3) : Erythrocyte invasion by 
merozoite; (4) : Gametocytes taken up by mosquito; (5) : Production of infectious sporozoite in 
anopheline mosquito. 
 
1.3. The biology of P. falciparum in human host erythrocytes 
The human malarial parasite, P. falciparum, inhabits the human erythrocyte in a 
parasitophorous vacuole (PV) during the asexual stage life cycle (Sargeant et al., 2006).  The 
PV develops during invasion of the host erythrocyte.  The vacuolar membrane functions as a 
selective semi-permeable barrier between the parasite and the erythrocyte cytoplasm through 
which parasite-encoded proteins known as exportome are exported to the erythrocyte cytosol 
and membrane (Ansorge  et al., 1996; Joiner, 1991).  As the parasite intra-erythrocytic 
development progresses, membranous structures referred to as Maurer’s clefts are formed in 
the erythrocyte cytoplasm.  Maurer’s clefts, usually located at the erythrocyte periphery, 
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extensively remodel the erythrocyte to form electron dense structures termed knobs. 
Examples of exported parasite proteins include knob-associated histidine-rich protein 
(KAHRP) (Pologe et al., 1987; Triglia et al., 1987) and P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) (Baruch et al., 1995; Kilejian and Jensen, 1977).  PfEMP1 in particular 
has been implicated in the cytoadherence of the parasite-infected erythrocyte to the 
endothelial receptor cells of the blood vessels thus preventing removal by the spleen in 
human host.  The mode of export of parasite proteins into the host cells is thought to be 
dependent on a highly conserved Plasmodium export element (PEXEL) motif which has also 
been identified as host targeting (HT) signal (Hiller et al., 2004; Marti et al., 2004).  A few 
other parasite proteins known to be present in the exportome are kinases, phosphatases and 
members of the molecular chaperones most especially the highly conserved heat shock 
proteins (Hsps) (Kooij et al., 2006; Sargeant et al., 2006).  An example of exported molecular 
chaperones belonging to the hsp family include members of the Hsp40s namely, type I 
Hsp40s (J1), type II Hsp40s (J2), type III Hsp40s (J3) and type IV Hsp40s (J4) (Figure 1.3). 
 
 
 
 
  
 
 
 
Figure 1.3:  The location of different PfHsp40s within the parasite and the erythrocyte.  (Adapted 
from Rug and Maier, 2011).  (J1) Type I Hsp40s; (J2) Type II Hsp40s; (J3) Type III Hsp40s; (J4) 
Type IV Hsp40s. 
 
1.4. Molecular chaperones 
Molecular chaperones are groups of proteins implicated in promoting quality control in a cell, 
including protein aggregation suppression and facilitating the folding of non-native proteins 
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into correct native conformations without being part of the final structure (Walter and 
Buchner, 2002; Borges and Ramos, 2005).  In addition, molecular chaperones facilitate 
protein assembly, disassembly and protein transport to various subcellular compartments 
(Mayer and Bakau, 2005). The majority of the molecular chaperones identified belong to 
highly conserved Hsp family.  A number of these heat shock proteins are known to increase 
in expression levels upon exposure to heat shock while some proteins are proposed to be 
constitutively expressed (Watanabe, 1997).  For example, messenger RNA (mRNA) levels of 
Pfj1 are upregulated upon heat shock in P. falciparum infected erythrocytes whereas Pfj2 is 
proposed to be constitutively expressed in the erythrocytic stage parasite but decreases in 
expression upon heat shock (Watanabe, 1997).  Hsp70 and Hsp40 molecular chaperones have 
been extensively studied (Botha et al., 2011; Shonhai et al., 2008). 
 
1.4.1.  Heat shock protein 70 (Hsp70) 
Hsp70s, ubiquitous in cell compartments, are either constitutively expressed or inducible in 
response to cellular stress, for example an increase in temperature.  Hsp70 possesses an N-
terminal 44 kDa ATPase domain and a C-terminal peptide-binding domain subdivided into 
18 kDa ß-substrate binding and 10 kDa α-helical domains respectively (Flaherty et al., 1990; 
Wang et al., 1993).  The conserved C-terminal peptide sequence EEVD motif is involved in 
regulating the Hsp40 stimulated adenosine triphosphate (ATP) hydrolysis by Hsp70.  
Stimulation of ATP hydrolysis is crucial for the chaperone activity of Hsp70 (Szabo et al., 
1994).  In the ATP-bound state, Hsp70 has a low affinity for substrate protein whereas in the 
ADP-bound state Hsp70 has a high affinity for substrate (Suh et al., 1999).  Nucleotide 
exchange factors (NEFs) mediate nucleotide exchange to replace ADP with ATP thereby 
inducing a conformational change to facilitate substrate release (Liberek et al., 1991).  Hsp70 
function in partnership with co-chaperone Hsp40 in mediating protein folding, assembly and 
transport (Feldman and Frydman, 2000; Fink, 1999).   
 
 
 
Figure 1.4:  Diagrammatic representation of the domain organisation of Hsp70.  The domains 
shown are the ATPase domain and the peptide-binding domain that is subdivided into ß-substrate 
binding and α-helix subdomains.  
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1.4.2.  Heat shock protein 40 (Hsp40) 
Hsp40s are defined by the presence of a J-domain with approximately 70 amino acid region, 
similar to the J-domain of the Escherichia coli Hsp40 protein, DnaJ (Pellecchia et al., 1996).  
The J-domain structure has four α-helices (helices I-IV) and situated in a loop region between 
helices II and III is the highly conserved histidine-proline-aspartic acid (HPD) tripeptide 
motif (Figure 1.5) (Botha et al., 2007).  This domain is orientated such that charged residues 
in helix II can interact correctly with the ATPase domain of partner Hsp70 (Hennessy et al., 
2005; Tsai and Douglas, 1996).  Mutations in the HPD motif result in loss of functional 
interactions between Hsp40 and Hsp70 (Hennessy et al., 2005; Laufen et al., 1999; Mayer 
and Bukau, 2005; Tsai and Douglas, 1996; Wittung-Stafshede et al., 2003).  The HPD motif 
is essential for J-domain-based stimulation of the ATPase activity of Hsp70, resulting in the 
stabilisation of the substrate-bound form of Hsp70.  Helices II and III mediate domain 
interaction with Hsp70 whereas helix IV may modulate the specificity or affinity of the 
Hsp70-Hsp40 chaperone partnership (Hennessy et al., 2005). 
 
 
 
 
 
 
 
 
 
Figure 1.5: Ribbon representation of the J domain of E. coli DnaJ (1XBL) (Pellecchia et al., 1996).  
The conserved HPD motif is represented in purple sticks.  Helices I-IV are labelled.  N represents the 
amino terminus.  C represents carboxyl terminus.   
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1.4.2.1.  Classification of Hsp40s 
Hsp40s are classified into four groups based on their domain organisation (Figure 1.6).  Type 
I Hsp40s consist of an N-terminal J-domain with a highly conserved HPD motif, a 
glycine/phenylalanine (G/F)-rich region, a cysteine-rich zinc finger domain and a less 
conserved C-terminal substrate-binding domain.  Type II Hsp40s contain all the domains 
typical of type I Hsp40s except that the zinc-finger region is absent. Types III Hsp40s only 
possess a J-domain with conserved HPD motif.  Type IV Hsp40s are characterised by the 
presence of a J-domain but the HPD motifs are not conserved (Cheetham and Caplan, 1998; 
Botha et al., 2007).  Type I and type II Hsp40s, in partnership with Hsp70, are involved in 
processes which include protein folding, refolding of misfolded proteins, assembly of 
proteins and protein degradation. Type III Hsp40s, tend to perform more highly specialised 
functions such as regulation of other chaperone (Cheetham and Caplan, 1998; Walsh et al., 
2004).  Since the normally conserved HPD motif of the J-domain in the type IV Hsp40s 
varies, it is suggested that this variation may hinder interaction between Hsp40 and Hsp70, 
and thus this class of Hsp40s seem to function in an unknown manner (Botha et al., 2007).  
 
 
 
 
 
 
 
 
 
 
Figure 1.6:  Diagrammatic representation of the domain organisation of the four types of Hsp40s.  
I: type I Hsp40; II: type II Hsp40; III: type III Hsp40; IV: type IV Hsp40.   The subdomains shown 
are the J domain, the G/F region and the zinc finger region.   
 
 
 
_____________________________________________________________Literature Review 
 
Page | 10  
 
The G/F region is thought to be important in the regulation of the substrate-binding 
capabilities of Hsp70 possibly through stabilisation of the Hsp70-substrate complex 
optimisation of substrate selection or facilitating the transport of substrate from Hsp40 to 
Hsp70 (Genevaux et al., 2002; Han and Christen, 2003). 
The zinc-binding domain could potentially play a role in stabilising Hsp40 tertiary structure 
as this domain is characterised by the availability of four cysteine-repeat sequences capable 
of co-ordinating binding of two zinc ions (Greene et al., 1998; Martinez-Yamout et al., 
2000).  Furthermore, the zinc-binding domain and the C-terminus could possibly serve as a 
requirement for substrate binding (Han and Christen, 2003). 
The C-terminal domain is associated with substrate binding in types I and II Hsp40s, and is 
also crucial for the interaction of Hsp40 with the non-native polypeptides through 
hydrophobic interactions (Borges et al., 2005; Wu et al., 2005).  It has been suggested that 
Hsp40 may bind the non-native polypeptides prior to transferring them to Hsp70 for 
recognition and binding (Li et al., 2009). 
 
1.5.  Protein quality control in the endoplasmic reticulum (ER) 
The endoplasmic reticulum (ER) is a membrane-bound organelle within the cytoplasm of 
eukaryotic cells involved in protein folding, quality control and protein degradation (Ellgaard 
and Helenius, 2001; Sitia and Braakman, 2003).  Secretory and membrane proteins undergo 
quality control in the ER that separate correctly folded proteins from unassembled and 
terminally misfolded proteins.  Correctly folded proteins are transported to their final 
destination. Unassembled proteins are retained and refolded in the ER.  Terminally misfolded 
proteins are subjected to degradation by the 26S proteasome in a process known as ER-
associated degradation (ERAD) following retrotranslocation into the cytosol (Brodsky and 
McCracken, 1999; Plemper et al., 1999; Sommer and Wolf, 1997).  The conditions leading to 
protein misfolding include genetic mutations, heat shock and oxidative stress. The 
accumulation of unfolded or misfolded proteins in the ER activates a signal transduction 
cascade referred to as the unfolded protein response (UPR) (Hoseki et al., 2010).  The UPR 
induces the expression of ER-resident chaperone proteins such as BiP, PDI and ERAD 
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components involved in boosting the folding capacity of the ER and facilitate the removal of 
accumulating misfolded proteins (Ellgaard et al., 1999; Malhotra and Kaufman, 2007). 
 
1.5.1.  ER-associated degradation (ERAD) 
The ERAD pathway involves degradation of terminally misfolded glycoprotein and non-
glycosylated proteins (Figure 1.7).  For ERAD of non-glycosylated proteins, ER-resident 
chaperone BiP and protein-disulfide isomerase (PDI) recognises misfolded proteins and 
recruits them to ERdj5.  ERdj5, a disulfide reductase and essential for degradation of 
incorrectly folded proteins in the ER interact with BiP through the J-domain (Pathway 1).  
For ERAD of glycosylated proteins, misfolded glycoproteins are first recognized by calnexin 
(CNX) or calreticulin (CRT), transferred to ER degradation enhancing α-mannosidase-like 
protein (EDEM) and then to Endoplasmic Reticulum DnaJ protein 5 (ERdj5).  ERdj5 
interacts with EDEM and thus facilitates ERAD by cleaving disulphide bonds of misfolded 
glycoproteins and prevents oligomer formation (Pathway 2).  In both ERAD pathways, ERdj5 
is required in enhancing the degradation of terminally misfolded proteins (Ushioda et al., 
2008). 
 
 
 
 
 
 
 
 
 
Figure 1.7: ERAD pathways for terminally misfolded glycoprotein and non-glycosylated proteins 
(Adapted from Ushioda et al., 2008).  (1) : ERAD pathway for non-glycosylated protein; (2) : ERAD 
pathway for glycosylated protein. 
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1.5.2.  ER-resident chaperone, BiP 
Immunoglobulin binding protein, BiP, also termed glucose regulated protein 78kDa (GRP-
78) is a member of the Hsp70 family, and the most abundant ER chaperone.  BiP was initially 
termed immunoglobulin binding protein because of its role in the assembly of 
immunoglobulins (Haas and Wabl, 1983).  BiP has an ATPase domain and a peptide-binding 
domain that undergo repetitive cycles of ATP hydrolysis and nucleotide exchange that 
promotes binding and release of the unfolded protein respectively (Minami et al., 1996).  The 
ATPase cycle is regulated by Hsp40-type co-chaperones which stimulate ATPase hydrolysis 
and proteins involved in nucleotide exchange (Shen and Hendershot, 2005).  In addition to its 
role in facilitating protein folding and assembly, BiP plays a role in identifying and targeting 
misfolded proteins for proteasomal degradation.  Furthermore, BiP preserves the permeability 
barrier of the ER translocon during early stages of protein translocation (Hamman et al., 
1998), serves as a sensor for ER stress (Bertolotti et al., 2000; Shen et al., 2002) and 
functions in the maintenance of ER calcium stores (Lievremont et al., 1997).   
 
1.5.3.  Protein-disulfide isomerase (PDI) 
Protein-disulfide isomerase (PDI) is a 55 kDa protein in the ER which serves to assist 
secretory proteins in attaining the correct disulfide arrangement.  PDI catalyses thiol-disulfide 
formation, isomerisation and reduction (Schwaller et al., 2003).  PDI has two thioredoxin-like 
catalytic domains, one at the amino terminus and the other at the carboxyl terminus that 
usually contain a characteristic CXXC active-site motif (Edman et al., 1985; Ellgaard and 
Ruddock, 2005).  Each active motif has two cysteines residues in the sequence which mediate 
catalytic activities (Schwaller et al., 2003).  In addition to PDI, four yeast homologues has 
been identified namely, Mpd1p, Mpd2p, Eug1p and Eps1p (Sevier and Kaiser, 2002; Tu and 
Weissman, 2004).  19 PDI family proteins have been found in mammals including human 
ERdj5 (Cunnea et al., 2003; Hosoda et al., 2003). 
 
1.5.4.  ER-resident protein, ERdj5 
Seven resident ER proteins with J domains (ERdj) have been identified in mammals (Table 
1.1).  ERdj5, also termed JPDI (J-domain containing PDI-like protein) is a member of the 
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PDI family which has been identified as an ER resident J-protein.  In addition to having a J-
domain, ERdj5 has four thioredoxin-like domains (Figure 1.8) that function as a co-
chaperone for the ER resident Hsp70 chaperone, BiP (Cunnea et al., 2003; Hosoda et al., 
2003).  Several functions of ERdj5 have been reported.  Ushioda et al. (2008) identified 
ERdj5 as an EDEM interacting protein and that it serves as a disulfide reductase that 
mediates the removal of incorrectly folded proteins.  ERdj5 and ERdj4 have been reported by 
Dong et al. (2008) to participate in the ERAD of non glycosylated substrate.  Homologue of 
human ERdj5 has been identified in P. falciparum Hsp40, Pfj2 (Botha et al., 2007). 
 
 
 
Figure 1.8:  Schematic representation of the domain structure of ERdj5.  J represents the J-domain.  
The four thioredoxin domains are labelled. 
 
Table 1.1:  Mammalian ERdj proteins  
ERdj protein Molecular weight (kDa) Yeast homologue 
ERdj1/Mtj1a,b 63 Sec63a 
ERdj2/hSec63c,d 85 Sec63b 
ERdj3/HEDJe,f,g 43 Scj1c 
ERdj4/Mdj1h,i 25 None 
ERdj5/JPDIj,k 96 None 
ERdj6/p58IPK l 58 None 
ERdj7m 42 None 
aBrightman et al. (1995); bChevalier et al. (2000); cSkowronek et al. (1999); dTyedmers et al. (2000); 
eBies et al. (1999); fLau et al. (2001); Yu et al. g(2000); hProls et al. (2001);  iShen et al. (2002); 
jCunnea et al. (2003); kHosoda et al. (2003); lYan et al. (2002); mZahedi et al. (2009). 
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1.6.  P. falciparum heat shock proteins  
The Hsp40s are a family of molecular co-chaperone that regulates the activity of Hsp70s.  
The Hsp40s are characterised by a highly conserved J-domain that promotes interaction with 
the Hsp70s (Genevaux, 2002).  At least six PfHsp70s have been identified in P. falciparum 
(Peterson et al., 1988; Sargeant et al., 2006).  The genome of P. falciparum codes for 43 
Hsp40s which are classified into four types, namely type I, type II, type III and type IV 
(Botha et al., 2007). 
 
 
1.6.1.  P. falciparum Hsp70s 
 
The P. falciparum genome encodes at least six PfHsp70s (Peterson et al., 1988; Sargeant et 
al., 2006) (Table 1.2).  PfHsp70 has domains typical of Hsp70 as described in section 1.4.1.  
PfHsp70 are ubiquitous and expressed in the various stages of the P. falciparum life cycle 
(Sharma, 1992).  High levels of PfHsp70s are particularly present in the liver of the human 
host during the asexual reproduction of the parasite (Kumar and Zheng 1992).  An increase in 
temperature is known to cause a rise in the expression level of PfHsp70 which suggests that 
PfHsp70 may play an essential role in the survival of the parasite (Biswas and Sharma, 1994; 
Joshi et al., 1992).   
 
Table 1.2: P. falciparum Hsp70s 
Protein Chromosome kDa Cellular localisation  
PfHsp70-x 7 73.2 Cytoplasmc 
PfHsp70-y 13 108.2 ERc 
PfHsp70-z 7 100 Cytoplasmc 
PfHsp70-1a 8 73.9 Nucleus and cytoplasmd 
PfHsp70-2a,b 9 72.4 ERd 
PfHsp70-3a 11 73.3 Mitochondrionc,e 
aSharma (1992); bNyalwidhe and Lingelbach (2006); cSargeant et al. (2006); dKumar et al. (1991); 
eŠlapeta and Keithly (2004). 
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Amongst the six PfHsp70s, PfHsp70-1 has been well studied.  PfHsp70-1 has generated 
much research attention in terms of its chaperone properties for possessing ATPase activity 
and for the ability to suppress protein aggregation (Matambo et al., 2004; Ramya et al., 2006; 
Shonhai et al., 2008).  PfHsp70-1 primarily localises in the cytosol and in the nucleus 
(Kappes et al., 1993).  The localisation of PfHsp70-1 in the nucleus is enhanced in response 
to heat stress (Kappes et al., 1993).   
PfHsp70-1 is approximately 74 kDa in molecular mass and has a C-terminal EEVD motif.  
This EEVD motif binds to co-chaperone, for example, Hop, to facilitate protein interaction 
(Demand et al., 1998).  PfHsp70-1 shares a high amino acid sequence identity to another 
PfHsp70, namely, PfHsp70-x.  PfHsp70-x is approximately 74 kDa in molecular mass and 
has a C-terminal EEVN motif.  PfHsp70-x could be an alternate cytosolic PfHsp70, however, 
information regarding the role of PfHsp70-x is minimal.  Due to the fact that PfHsp70-1 
shares a high amino acid sequence identity and both possesses a highly conserved bipartite 
nuclear localisation signals (Robbins et al., 1991) suggests that PfHsp70-x may move to the 
nucleus (Shonhai et al., 2007). 
According to a report by Nyalwidhe and Lingelbach (2006), PfHsp70-1is present in the 
parasitophorous vacuole and has also been detected in the Maurer’s clefts (Vincensini et al., 
2005).  This suggests that the protein could possibly be exported to the erythrocyte (Shonhai 
et al., 2007).  PfHsp70-1 has been experimentally shown to have a high basal ATPase activity 
and ATP-dependent chaperone activity in vitro (Matambo et al., 2004; Ramya et al., 2006). 
In vivo studies of PfHsp70-1 shows that the protein is capable of reversing the 
thermosensitivity of an E. coli DnaK mutant strain (Shonhai et al., 2005).  In addition, 
PfHsp70-1 has a functional linker region and mutations in this region of the protein result in 
loss of functionality in vivo (Shonhai et al., 2005).  According to Shonhai et al. (2005) there 
is a possible inter domain interaction using chimeric protein from the ATPase domain of E. 
coli DnaK and the peptide-binding domain of PfHsp70-1in E. coli DnaK756 cells.  
The PfHsp70 possesses a translation initiation factor known as eIF-2α.  The phosphorylation 
of eIF-2α inhibits protein synthesis (Surolia and Padmanaban, 1991).  The PfHsp70 
suppresses eIF-2α phosphorylation through the activity of a heme-regulated kinase hence 
facilitates protein synthesis (Ramya et al., 2007).  In addition, Ramya et al. (2007) suggested 
that antimalarial, 15-deoxyspergulain (DSG), inhibit protein synthesis. Furthermore, DSG is 
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capable of modulating PfHsp70-1 activity through possible interaction with the EEVD motif 
of the protein.  The close proximity of the EEVD motif to the peptide-binding domain may 
inhibit protein folding through substrate-binding interference by PfHsp70-1 (Shonhai et al., 
2007).  In a recent study by Cockburn et al. (2011) PfHsp70-1 is shown to be inhibited by 
small molecule modulators, namely, malonganenone A-C, lapachol and bromo-ß-lapachona 
in malate dehydrogenase based aggregation suppression assays. Growth inhibition assays is 
also performed using P. falciparum 3D7-infected erythrocytes to show that all of the 
compounds with the exception of malonganenone are able to inhibit the growth of PfHsp70-
1.  A co-chaperone of Hsp70, P. falciparum heat shock protein 70 interacting protein (Hip) is 
capable of modulating the PfHsp70-1 and PfHsp70-3 chaperone function in vitro (Ramya et 
al., 2006). 
 
1.6.2.  P. falciparum Hsp40s 
 
1.6.2.1. Type I PfHsp40s 
The type I PfHsp40s, characterised by the presence of J-domain, G/F region, cysteine-repeat 
and C-terminal region consists of two PfHsp40s (Cheetham and Caplan, 1998).  These 
include PFD0462w (Pfj1, PfDnaJA) and PF14_0359 which are proposed to exhibit house-
keeping properties within the parasite because the export element, PEXEL/HT motif, is 
absent (Watanabe, 1997; Botha et al., 2007). 
The mRNA and protein level of Pfj1 increases upon heat shock (Watanabe, 1997; Nicoll et 
al., 2007).  In vivo complementation studies have shown that the replacement of the J-domain 
of a thermosensitive E. coli strain (OD259) with the J-domain from Pfj1 reverses the 
thermosensitivity of these proteins (Nicoll et al., 2007).  Furthermore, Pfj1 interacts with the 
origin of replication in the apicoplast genome, therefore, the protein has been proposed to be 
associated in the replication of a P. falciparum apicoplast DNA (Kumar et al., 2010).  Pfj1 
has also been shown to stimulate the protein refolding activity of PfHsp70-1 in vitro (Misra 
and Ramachandran, 2009).   
PF14_0359 co-localises in the parasite cytoplasm with PfHsp70-1 and assists in suppressing 
protein aggregation in vitro (Botha et al., 2011).  The observation that the PF14_0359 
stimulates the rate of ATP hydrolysis in the parasite and human Hsp70, and that these 
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ATPase activities are inhibited by small molecule modulator was first elucidated by Botha et 
al. (2011). 
 
1.6.2.2. Type II PfHsp40s 
The type II PfHsp40s differs from type I in that the cysteine-repeat region is absent.  In this 
category, nine PfHsp40s have been identified (Table 1.3).  Three of these PfHsp40s including 
PFA0660w, PFB0090c and PFE0055c bears the export motif (Bhattacharjee et al., 2008; 
Külzer et al., 2010).  None of the PfHsp70s exhibit an export element and no clear 
relationship between the type II PfHsp40 and PfHsp70 have been defined.  This has prompted 
the assumption that the exported type II PfHsp40s interact with human Hsp70 (Banumathy et 
al., 2002).  The exported co-chaperones might be involved in the translocation of proteins 
across the parasite vacuole membrane while some of the non-exported co-chaperones might 
play a role in the cytoprotection of the parasite during cell stress (Nyalwidhe and Lingelbach, 
2006; Rug and Maier, 2011).  PFA0660w and PFE0055c have been reported to localise in the 
erythrocyte cytoplasm (Bhattacharjee et al., 2008; Külzer et al., 2010).  PFE0055c partially 
co-localises with the Maurer’s cleft marker skeleton-binding protein 1 (SBP1) (Bhattacharjee 
et al., 2008).  In a recent study, PFA0660w and PFE0055c are shown to associate with 
mobile dot-like structures in the erythrocyte cytoplasm (Külzer et al., 2010).  The co-
localisation of the two proteins with the known Maurer’s cleft markers did not occur and the 
dot-like structures appeared smaller than the Maurer’s clefts.  Therefore, it is suggested that 
PFA0660w and PFE0055c localises in an unknown organelle which is referred to as the J-
dots. 
The mRNA expression level of PFL0565w (Pfj4) is shown to increase upon heat shock 
(Watanabe, 1997).  Pfj4 has a functional J-domain (Nicoll et al., 2007).  Co-localisation and 
immunoprecipitation studies of Pfj4 with PfHsp70-1 have been reported (Pesce et al., 2008).  
LaCount et al. (2005) has reported possible interaction between Pfj4 and the P. falciparum 
gonial cell neoplasm protein 20 (PFGCN20) but this interaction has not been experimentally 
validated. PFGCN20 potentially plays a role as an ATP-binding subunit of an ABC 
transporter.  The interaction between these proteins suggests possible involvement in protein 
transfer across membranes. 
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PF11_0099 (Pfj2) has a C-terminal ER retention signal, DDEL, and exhibits similarities with 
human ER-resident protein ERdj5 (Botha et al., 2007).  According to a previous report by 
Ushioda et al. (2008), ERdj5 serve as a reductase in facilitating protein quality control 
through cleaving of disulfide bonds of misfolded proteins.  The destabilisation of Pfj2 in P. 
falciparum may affect the parasite survival which suggests the protein could serve as a 
potential drug target. 
Table 1.3: P. falciparum type II Hsp40s  
Locus
a
 Chromosome kDa 
MAL13P1.277 13 24.3 
PFA0660w 1 47 
PFB0090c 2 48.3 
PFB0595w 2 37.4 
PFE0055c 5 46.4 
PFF1415c 6 44.7 
PFL0565w 
PF11_0099 
PF14_0137 
12 
11 
14 
28 
62.4 
45.2 
aBahl et al. (2003) 
 
1.6.2.3. Type III PfHsp40s 
 The largest and most diverse group of Hsp40s in P. falciparum are the type III Hsp40s.  20 
type III Hsp40s are encoded in the P. falciparum genome.  They are characterised by the 
presence of a J-domain and are thought to be more specialised in their interactions with 
Hsp70 (Kelly, 1998; Young et al., 2004).  The functions and locations of these proteins are 
still unknown but four, that is, PF10_0378 (Pfj3), PF11_0513, PFB0920w and PFL0055c are 
predicted to contain a PEXEL/HT motif and can thus be exported into the host cell.  The 
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mRNA expression level of Pfj3 has been reported to significantly increase upon heat shock 
(Watanabe, 1997). 
 
1.6.2.4. Type IV PfHsp40s 
P. falciparum genome encodes 12 type IV Hsp40s, ten of which are predicted to contain the 
PEXEL/HT motif.  PfHsp40 type IV contains a J-domain with a variation in the normally 
conserved HPD motif (Botha et al., 2007).  Variation in the HPD motif stops interaction 
between Hsp40 and Hsp70. These proteins are unique to the parasite in that there are no 
human homologues. Of the ten proteins predicted to have the PEXEL motif, four are 
members of the ring-infected erythrocyte surface antigen (RESA) while the remaining six are 
members of the mature erythrocyte surface antigen (MESA).  RESA and MESA interacts 
with erythrocyte membrane skeleton (Da Silva et al., 1994; Foley et al., 1991; Coppel et al., 
1988).  The presence of the RESA protein encoded in the four type IV PfHsp40s imparts 
resistance to heat shock, thus protecting the parasite from heat-induced damage during febrile 
episodes (Silva et al., 2005). 
  
1.6.3.  P. falciparum Hsp40, Pfj2 
Pfj2 has been identified as a type II Hsp40 consisting of a J-domain with conserved HPD 
motif, G/F region and a thioredoxin-like domain (Figure 1.9) (Botha et al., 2007).  
Bioinformatic analysis has revealed that Pfj2 is 62.4 kDa in molecular size with 540 amino 
acids residues.  Pfj2 is thought to possess a putative ER signal sequence and a putative 
PEXEL motif represented by RQLAK (Botha et al., 2007).  The analysis also revealed the 
presence of an ER retension motif represented by DDEL in the amino acid sequence of Pfj2. 
 
 
Figure 1.9: Schematic representation of the domain structures of Pfj2.  J represents the J-domain.  
The G/F region represents the glycine/phenylalanine region.  The thioredoxin, CSHC, domains are 
labelled.  The position of the putative ER signal sequence is indicated.  The position of the putative 
PEXEL motif, RQLAK, is labelled.  The ER retension motif, DDEL, is labelled.  
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Studies have shown that the mRNA expression levels of Pfj2 decreases upon exposure to heat 
shock (Watanabe, 1997).  Localisation studies of Pfj2 within the infected erythrocyte or 
parasite is yet to be proven experimentally. 
Pfj2 has been identified as a P. falciparum Hsp40 chaperone that may potentially be involved 
in protein quality control in the ER, but has not been well studied and documented in the 
literature.  Pfj2 chaperone is particularly interesting as it is potentially homologous to the 
human ER Hsp40, ERdj5 due to the domain similarity.  ERdj5 has been shown to assist 
protein quality control by cleaving disulfide bonds of misfolded proteins in the ER as a result 
of it reductase activity (Ushioda et al., 2008).  Pfj2 chaperone might well act in the same way 
to facilitate quality control of protein in P. falciparum thereby promoting survival of the 
parasite. The question therefore remains whether Pfj2 chaperone helps in the quality control 
of proteins within the parasite which can only be answered by characterising the Pfj2. 
 
1.7.  KNOWLEDGE GAP 
P. falciparum encodes chaperone proteins including Pfj2.  This protein has not been well 
characterised and little information regarding its biochemistry is available.  Pfj2 evokes 
interest as it shows a degree of homology to the human ERdj5.  Given that ERdj5 assists 
protein quality control in the ER, it is possible that Pfj2 performs a similar function in P. 
falciparum thereby promoting parasite survival in the cell.  Given that many anti-malarial 
drugs are now becoming less effective, biochemical characterisation of Pfj2 could provide 
more information on its potential as a drug target for the control of an important and 
devastating human disease. 
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1.8.  RESEARCH OBJECTIVES 
1.8.1.  Hypothesis  
Pfj2, a Hsp40 chaperone is potentially homologous to human ER Hsp40, ERdj5, a resident 
protein of the endoplasmic reticulum (ER) that promotes protein quality control by 
facilitating the degradation of misfolded proteins and may perform a similar function.  
 
1.8.2.  Broad objective 
The overall aim of this study is to express and purify His6-Pfj2 in a bacterial system, and 
investigate the ability of the protein to stimulate the chaperone activity of the mammalian ER 
Hsp70, BiP using ATPase assays. 
 
1.8.3.  Specific objectives  
 To perform a bioinformatics analysis of Pfj2 to compare domain similarities and 
identities with typical type II Hsp40s 
 To clone the codon-optimised Pfj2 coding sequence into a prokaryotic pQE30 
expression vector to enable over-production of a His6-Pfj2    
 To express His6-Pfj2 and His6-BiP in E. coli M15[pREP4] cells to determine 
protein production 
 To purify recombinant His6-Pfj2 and His6-BiP in E. coli M15[pREP4] cells for 
use in ATPase assays 
 To investigate whether His6-Pfj2 stimulates the ATPase activity of mammalian 
His6-BiP. 
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Chapter 2 
Methodology 
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2.1.  Introduction 
This chapter describes the methodology used to obtain purified His6-Pfj2 for use in ATPase 
assays. The experimental procedures included cloning of a codon-optimised, truncated gene 
sequence into the pQE30 vector followed by bacterial expression and purification of the 
protein under denaturing conditions using nickel affinity chromatography. Finally, ATPase 
assays were employed to determine the ability of His6-Pfj2 to stimulate the chaperone activity 
of mammalian His6-BiP. Prior to cloning, a bioinformatic analysis of the Pfj2 protein 
sequence was conducted to determine the degree of similarities and identities with other type 
II Hsp40 proteins namely, human ERdj5, S. cerevisiae Sis1, human Hsj1a and human 
DnaJB4.  An analysis of the Pfj2 domains was also performed to identify the putative ER 
targeting and retention signals. 
 
2.2.  Bioinformatic analysis:  
2.2.1. Sequence retrieval and alignment 
Protein and nucleotide sequences for Pfj2 (Locus: PF11_0099) and PfBiP (Locus: PFI0875) 
were retrieved from PlasmoDB (http://PlasmoDB.org) (Bahl et al., 2003).  Human ERdj5 
(Accession: AAN73271.1), Saccharomyces cerevisiae Sis1 (Accession: CAA95866.1), 
human Hsj1a (Accession: AAA09034.1), human DnaJB4 (Accession: NP_008965.2), 
hamster GRP-78/BiP (Accession: P07823.1) and S. cerevisiae BiP (Accession: EDN63302.1) 
protein sequences were downloaded from the NCBI website (http://www.ncbi.nlm.nih.gov). 
The amino acid sequence of Medicago sativa MsHsp70-1 (EMBL-Bank CDS: AAV98051) 
was retrieved from the EMBL-EBI website (http://www.ebi.ac.uk). BioEdit v7.0.9 software 
was used to generate sequence alignments based on the ClustalW Multiple alignment tool 
(Thompson et al., 1994).  ApE 2.0.39 software was used to generate the amino acid 
translation and alignment of the database and codon-optimised nucleotide sequences of Pfj2. 
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2.2.2. Codon-optimisation of the Pfj2 coding region 
Domain analysis of Pfj2 to identify ER targeting and retention signals was performed using 
Phobius (Käll et al., 2007). The ER signal sequence was not included in the sequence on 
which to base the synthesis of Pfj2 coding region.  Thus, to facilitate recombinant protein 
expression of Pfj2 in Escherichia coli, the Pfj2 coding region (31-510 amino acids) was 
codon-optimised. The codon-optimised Pfj2 nucleotide sequence was synthesised by 
GenScript (USA) and supplied as a pUC57-Pfj2 construct. To facilitate cloning of the 
sequence into pQE30, recognition sites for BamHI and KpnI were incorporated into the 5’ 
and 3’ ends of the nucleotide sequence respectively. 
 
2.3.  Cloning of Pfj2 into pQE30 expression vector 
2.3.1. Materials 
Ampicillin was purchased from Roche (USA).  BamHI, KpnI, Lambda DNA, Pst1, T4 DNA 
ligase, dNTPs, Pfu DNA polymerase and DpnI were obtained from Promega (USA).  
Agarose was purchased from Lonza (USA).  pQE30 forward (5'-ggagaaattaactatgagagg-3') 
and reverse (5'-gttctgaggtcattactgg-3') primers were obtained from Qiagen (Germany).  
pQE30 was purchased from Qiagen (USA).  E. coli JM109 cells [endA1 glnV44 thi-1 relA1 
gyrA96 recA1 mcrB+ Δ(lac-proAB) e14- [F' traD36 proAB+ lacIq lacZΔM15] hsdR17(rK
-
mK
+)] were purchased from Promega (USA).   
 
2.3.2. Preparation of E. coli competent cells 
Yeast tryptone (YT) broth (1.6% tryptone, 1% yeast extract, 0.5% NaCl) and YT agar (YT 
supplemented with 1.5% bacteriological agar) containing 100 μg/ml of ampicillin were 
autoclaved and used as growth media. A colony of E. coli JM109 cells was used to inoculate 
5 ml of YT broth. The culture was grown overnight in a shaking 37⁰C incubator and the 
following day diluted 1/200 into 50 ml YT broth and grown to mid-log phase (A600=0.3-0.6).  
The cells were transferred into 250 ml centrifuge tubes and harvested by centrifugation at 
5000xg for 5 minutes at 4⁰C. The pelleted cells were resuspended in 50 ml of ice-cold 0.1 M 
MgCl2 and incubated on ice for 20 minutes. Following centrifugation at 5000xg for 5 minutes 
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at 4⁰C, the cells were resuspended in 25 ml of ice-cold 0.1 M CaCl2 and placed on ice for 1-2 
hours. The centrifugation step was repeated. Cells were resuspended in 5 ml of ice-cold 0.1 
M CaCl2 containing 10% glycerol and stored at -80⁰C in 100 μl aliquots for future use.   
 
2.3.3. Transformation of E. coli JM109 cells  
Competent E. coli JM109 cells (100 μl) were mixed with 100 ng plasmid DNA and incubated 
on ice for 30 minutes.  Thereafter, the mixture was heat-shocked for 2 minutes at 42⁰C, cold-
shocked on ice for 2 minutes and incubated for 1 hour with 900 μl YT broth in a 37⁰C 
shaking incubator. Cells were plated onto YT agar plate containing ampicillin (100 μg/ml) 
and incubated at 37⁰C overnight. A single colony was inoculated into 5 ml YT broth with 100 
μg/ml ampicillin and grown at 37⁰C for 12 hours.  The transformed culture was stored at -
80⁰C in aliquots of YT broth containing 15% glycerol.  
 
2.3.4. Plasmid DNA extraction and restriction digestion  
Plasmid DNA was extracted using the QIAprep® Spin Miniprep Kit (Qiagen, USA) 
according to the manufacturer’s instructions and eluted in 30 μl TE buffer (10 mM Tris-Cl, 1 
mM EDTA, pH 8). Plasmid DNA was digested with BamHI and KpnI in a total reaction 
volume of 20 μl. The reaction was incubated at 37⁰C for 2 hours.  An aliquot (3 μl) of gel-
loading buffer (0.25% bromophenol blue, 10% SDS, 30% glycerol) was added and the digest 
was analysed by agarose gel electrophoresis (section 2.3.5).   
 
2.3.5. Agarose gel electrophoresis 
All samples were analysed by 0.8% agarose gel electrophoresis in TBE buffer (90 mM Tris, 
pH 8.3, 90 mM boric acid, 2 mM EDTA,) containing 0.5 μg/ml ethidium bromide.  A DNA 
ladder of λ DNA digested with PstI served as molecular marker. Samples were run at 100 V 
for approximately 1 hour. The DNA bands were visualised and pictures acquired using a 
ChemiDocTM EQ (BioRad, USA). The DNA band of interest was gel-purified using the 
ZymocleanTM Gel DNA Recovery Kit according to the manufacturer’s instructions.   
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2.3.6. Ligation and screening of the codon-optimised Pfj2 into pQE30  
The gel-purified DNA was ligated into the pQE30 vector digested with BamHI and KpnI to 
generate pQE30-Pfj2. The ligation reaction which included 100 ng vector DNA, 17 ng insert 
DNA, 10 x ligation buffer and 0.1-1 units of T4 DNA ligase was assembled to a final volume 
of 10 μl, and incubated at 4⁰C overnight. An empty vector control reaction was prepared 
which comprised the above-mentioned reagents with the exception of insert DNA. The 
ligation was transformed into competent E. coli JM109 cells, and plasmid DNA extracted as 
described in sections 2.3.3 and 2.3.4. The successful cloning of pQE30-Pfj2 was confirmed 
by restriction analysis using BamHI and KpnI followed by agarose gel electrophoresis.  
Plasmids with 1549 bp inserts were sequenced by preparing a total reaction volume of 20 μl 
which consisted of 300 ng of plasmid DNA, 3.2 pmol of pQE30 primers, 5x BigDye buffer 
and 4 μl BigDye Terminator V3.1 (Applied Biosystems, USA). The PCR amplification 
parameters were 94⁰C for 3 minutes, followed by 30 cycles at 94⁰C for 30 seconds, 55⁰C for 
30 seconds, 72⁰C for 2 minutes, and a final extension at 72⁰C for 5 minutes. The 
amplification product was cleaned using the Zymo Research DNA Clean and Concentrator-
5TM Kit (USA) according to the manufacturer’s instruction. The product was eluted with 10 μl 
of double distilled water and placed in a vacuum drier for 10 minutes.  DNA sequencing was 
performed based on the chain-termination method with the ABI Genetic Analyser 3100 
(Applied Biosystems, USA).  
 
2.3.7. Site-directed mutagenesis  
2.3.7.1. Primer design  
The primers generated for the purpose of deletion mutagenesis of pQE30-Pfj2 were designed 
using GeneRunnerTM (Hastings Software, USA) and synthesised by Inqaba Biotec (South 
Africa). Primers were designed to amplify a 1549 bp sequence of Pfj2.  The primer sequences 
are shown in Table 2.1. 
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Table 2.1: Primers used for site-directed mutagenesis 
Name of primer Sequence  Tm (⁰C)  GC (%) 
For-MpQE30-Pfj2 5’ - CCATCACCATCACATCCGATCCAATG - 3’ 76 50 
Rev-MpQE30-Pfj2 5’ - CATTGGATCGGATGTGATGGTGATGG - 3’ 76 50 
 
Reactions of 50 μl containing 100 ng pQE30-Pfj2, 5 μl of 10x reaction buffer, 5% DMSO, 25 
mM MgCl2, 10 mM dNTPs, 125 ng For-MpQE30-Pfj2, 125 ng Rev-MpQE30-Pfj2, and 2.5 U 
Pfu DNA polymerase were prepared. The amplification was performed in a GeneAmp PCR 
9700 thermocycler (Applied Biosystems, USA) according to the cycling parameters in Table 
2.2.  
Table 2.2:  Cycling parameters 
Number of cycles Temperature (⁰C) Time (seconds) 
1 95 30 
18 95 30 
 52 60 
 68 30 
1 68 420 
 
2.3.7.2. DpnI treatment and agarose gel electrophoresis  
The reaction mixture was cooled to 37⁰C and 10 μl of the mutagenesis product was kept for 
agarose gel electrophoresis analysis prior to DpnI treatment to remove parental plasmid.  
DpnI (10 U) was added to the reaction, centrifuged at 500x g for 1 minute and incubated at 
37⁰C overnight. Samples were analysed by 0.8% agarose gel electrophoresis as presented in 
Table 2.3. An aliquot of 100 ng of the DpnI treated mutagenesis product was transformed 
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into competent E. coli JM109 cells as described in section 2.3.3.  Plasmid DNA was extracted 
as described in section 2.3.4 and sequenced for verification.  
 
Table 2.3: Samples analysed on a 0.8% agarose gel 
Sample Volume (μl) 
PstI-digested λ DNA size marker 3 
Undigested pQE30-Pfj2, parental plasmid as 
a control 
10 
DpnI treated mutagenesis amplification  
product, pQE30-Pfj2 
10 
pQE30-Pfj2 restricted with BamHI as a 
control 
10 
pQE30-Pfj2 restricted with KpnI as a control 10 
 
 
2.4.  Bacterial expression of recombinant proteins 
2.4.1.Materials  
Mouse anti-His primary antibody was obtained from GE Healthcare (UK).  Anti-mouse IgG 
POD-labeled secondary antibody was purchased from Roche (USA). PageRulerTM Plus 
Prestained Protein Ladder was purchased from Fermentas (USA). The pQE10-BiP construct 
was a kind gift from Prof. Richard Zimmermann (Universität des Saarlandes, Germany).  E. 
coli M15[pREP4] cells [lac, ara, gal, mtl, recA+, uvr+, StrR, (pREP4: KanR, lacI)] were 
purchased from Qiagen (USA).   
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2.4.2. Expression of His6-Pfj2 and mammalian His6-BiP in E. coli M15[pREP4] cells 
Preparation of competent E. coli M15[pREP4] cells and transformation with pQE30-Pfj2 
were performed as described in sections 2.3.2 and 2.3.3, in the presence of ampicillin (100 
μg/ml) and kanamycin (50 μg/ml) for selection purposes. 
A single colony of E. coli M15[pREP4] cells transformed with the pQE30-Pfj2 was 
inoculated into 25 ml YT broth and the culture was grown in a shaking 37⁰C incubator 
overnight. The overnight culture was diluted 1/50 into 250 ml of YT broth and grown at 37⁰C 
until A600 was approximately 0.6. A pre-induction sample (1 ml) was collected. The 
remaining culture was induced with 1 mM IPTG and samples were collected every hour for 5 
hours and again after 12 hours.  The samples were centrifuged at 13000xg for 1 minute and 
the pellets resuspended in a volume of PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
2 mM KH2PO4 pH 7.4) equal to A600/0.5*100 μl. Samples were treated with SDS-PAGE 
sample buffer (0.5 M Tris, pH 6.8, 10% glycerol, 10% SDS, 5% 2-mercaptoethanol, 1% 
bromophenol blue) and boiled at 100⁰C for 5 minutes. Proteins were analysed by SDS-PAGE 
and Western immunoblotting using a mouse monoclonal anti-His IgG primary antibody and 
anti-mouse IgG POD-labeled secondary antibody.  
 
2.4.2.1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were analysed by 12% SDS-PAGE at 150 V for approximately 1 hour in 1x SDS-
PAGE running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). The protein bands were 
visualised by staining with Coomassie Brilliant Blue (0.2% Coomassie G-250, 40% 
methanol, 7% glacial acetic acid). The stain was removed after several washes with destain 
solution (40% methanol, 7% glacial acetic acid).  PageRulerTM Plus Prestained Protein 
Ladder was used as molecular marker.  
 
2.4.2.2. Western immunoblotting 
Proteins resolved by SDS-PAGE were transferred onto nitrocellulose membrane (Trans-Blot 
Transfer medium, BioRad, USA) in transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol) for 1 hour at 100 V with continuous stirring and cooling. To verify transfer, the 
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membrane was stained with Ponceau S (0.5% Ponceau S in 1% glacial acetic acid) and 
washed with distilled MilliQ water.  The membrane was blocked in TBS-T (50 mM Tris, pH 
7.5, 150 mM NaCl, 0.2% Tween-20) containing 5% non-fat milk powder overnight at 4⁰C.  
The membrane was incubated with mouse anti-His primary antibody diluted 1:5000 in 
blocking solution for 1 hour with shaking at room temperature, followed by 4x15 minutes 
washes with TBS-T. The membrane was subsequently incubated with anti-mouse IgG POD-
labeled secondary antibody, diluted 1:6000 in blocking solution for 1 hour with shaking.  
Proteins were detected using the Roche BM Chemiluminescence Western Blotting Kit and 
visualized using a ChemidocTM EQ (BioRad, USA). 
 
2.5. Solubility studies  
His6-Pfj2 was expressed in E. coli M15[pREP4] cells as described in section 2.4.2.  
Following an overnight induction with 1 mM IPTG, the 250 ml cell culture was harvested by 
centrifugation at 6000xg for 20 minutes at 4⁰C. The pellet was resuspended in 2.5 ml cold 
lysis buffer (10 mM Tris, pH7.5, 300 mM NaCl, 50 mM imidazole, 1 mM PMSF, 0.1 mg/ml 
lysozyme) and frozen at -80⁰C overnight in 1 ml aliquots. The cell lysate was rapidly thawed 
and sonicated five times for 30 seconds at 4⁰C. The cell lysate was centrifuged at 16000xg 
for 30 minutes at 4⁰C. The supernatant (soluble fraction) and the pellet (insoluble fraction) 
were resuspended in 1 ml of PBS, treated with 5x SDS-PAGE sample buffer and boiled for 5 
minutes at 100⁰C. The two fractions were analysed by SDS-PAGE (section 2.4.2.1) and 
Western immunoblotting (section 2.4.2.2).  
 
2.6.  Purification of His6-Pfj2 and mammalian His6-BiP 
2.6.1. Materials 
Urea, Imidazole, PMSF and lysozyme were purchased from Sigma-Aldrich (Germany).  
HisTrap affinity columns and Chelating Sepharose Fast Flow were purchased from GE 
Healthcare (Sweden). SnakeskinTM dialysis tubing was obtained from Thermo Scientific 
(USA).  
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2.6.2. Urea denaturing purification of His6-Pfj2 from E. coli M15[pREP4] cells 
An overnight culture of E. coli M15[pREP4] cells harbouring His6-Pfj2 was harvested by 
centrifugation at 6000xg for 20 minutes at 4⁰C. The pellet was resuspended in cold 
denaturing lysis buffer (8 M Urea, 100 mM Tris, pH 8, 300 mM NaCl, 10 mM imidazole, 1 
mM fresh PMSF) and frozen overnight at -20⁰C in 1 ml aliquots. The cells were rapidly 
thawed and sonicated five times for 30 seconds at 4⁰C. The cell lysate was centrifuged at 
16000xg for 30 minutes at 4⁰C. The supernatant was loaded onto a Ni2+-charged HisTrap 
column. The column was washed with cold wash buffer A (4 M Urea, 100 mM Tris, pH 8, 
300 mM NaCl, 50 mM imidazole), then with buffer B (2 M Urea, 100 mM Tris, pH 8, 300 
mM NaCl, 50 mM imidazole), and finally with buffer C (100 mM Tris, pH 8, 300 mM NaCl, 
50 mM imidazole) to remove unbound protein. The bound proteins were eluted in cold 
elution buffer (100 mM Tris, pH 8, 300 mM NaCl, 1 M imidazole) and dialysed using 
dialysis tubing in dialysis buffer (50 mM Tris, pH 8, 200 mM NaCl), treated with 5 x SDS-
PAGE sample buffer and boiled for 5 minutes. Purified protein with loaded amount of 0.954 
mg/L was separated by SDS-PAGE and Western immunoblotting as described in sections 
2.4.2.1 and 2.4.2.2.  Protein concentration was measured using a Thermo Scientific nanodrop 
spectrophotometer (USA).  Three independent His6-Pfj2 purification experiments were 
performed for future use in ATPase assays. 
 
2.6.3. Preparation of Ni
2+
-chelating sepharose beads  
An aliquot (250 μl) of sepharose beads was centrifuged at 500xg for 5 minutes.  The beads 
were resuspended in 5x volume (1250 μl) of distilled MilliQ water and again centrifuged at 
500xg for 5 minutes. An equal volume of 0.1 M NiSO4 was added to the beads and the 
sample was agitated for 15 minutes, followed by centrifugation at 500xg for 5 minutes. The 
beads were washed in 1250 μl of distilled MilliQ water in three consecutive washing steps 
with centrifugation at 500xg for 5 minutes between each step. The beads were resuspended in 
250 μl of lysis buffer.   
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2.6.3.1. Native purification of mammalian His6-BiP  
E. coli M15[pREP4] cells, expressing mammalian His6-BiP were harvested by centrifugation 
at 6000xg for 20 minutes at 4⁰C. The pellet was resuspended in cold native lysis buffer (10 
mM Tris, pH 7.5, 300 mM NaCl, 40 mM imidazole, 1 mM fresh PMSF, 0.1 mg/ml 
lysozyme) and frozen overnight at -80⁰C in 1 ml aliquots. The cells were rapidly thawed and 
sonicated five times for 30 seconds at 4⁰C. The cell lysate was centrifuged at 16000xg for 30 
minutes at 4⁰C. The supernatant was added to 500 μl of 50% (v/v) Ni2+-chelating sepharose 
beads prepared as described in section 2.6.3, for binding at 4⁰C for 4 hours with gentle 
agitation. The beads were centrifuged at 1500xg for 2 minutes to remove the unbound protein 
fraction and an aliquot (80 l) of unbound protein was prepared for SDS-PAGE and Western 
analysis. Thereafter, the beads were washed three times in cold wash buffer (10 mM Tris, pH 
7.5, 300 mM NaCl, 40 mM imidazole) and centrifuged at 1500xg for 2 minutes. The bound 
protein was eluted in cold elution buffer (10 mM Tris, pH 7.5, 300 mM NaCl, 100 mM 
imidazole) and dialysed with dialysis tube in dialysis buffer (10 mM Tris, pH7, 200 mM 
NaCl). Purified protein with loaded amount of 10.252 mg/L was separated by 12% SDS-
PAGE and detected by Western immunoblotting using mouse anti-His primary antibody and 
anti-mouse IgG POD-labeled secondary antibody.  Protein concentration was determined 
with a Thermo Scientific nanodrop spectrophotometer (USA).  Three independent His6-BiP 
purification experiments were performed for future use in ATPase assays. 
 
2.7.  ATPase assays of His6-Pfj2 and mammalian His6-BiP 
2.7.1. The phosphate standard curve 
Phosphate standard reactions were prepared from serial dilutions of 50 mM KH2PO4 with 
concentrations ranging from 0 to 6 nmol/μl. The reactions were added to 1x ATPase-buffered 
solution (100 mM Hepes, 100 mM MgCl2, 1 M KCl, 100 mM DTT) and 10% SDS before 
incubation at 37⁰C for 3 hours. The absorbance was read at 850 nm.  Excel 2007 software 
was used to analyse the result. 
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2.7.2. ATPase assays of His6-Pfj2 and mammalian His6-BiP using ammonium molybdate and 
ascorbic acid 
His6-Pfj2 and mammalian His6-BiP were purified as described in sections 2.6.2 and 2.6.3.1. 
Reactions of 1 ml (10 mM Hepes, 10 mM MgCl2, 20 mM KCl, 0.5 mM DTT, 0.4 μM His6-
BiP, 0.4 μM His6-Pfj2) were prepared and pre-incubated at 37⁰C for 5 minutes.  Thereafter, 
60 μl of ATP was added to start the reactions. The reactions remained at 37⁰C and 50 μl 
samples were collected in microtitre plate wells containing 50 μl of 10% SDS at 0, 15, 30, 60, 
120 and 180 minute intervals. Subsequently, 50 μl of 1% (w/v) ammonium molybdate in 1 M 
HCl, 50 μl of 6% (w/v) ascorbic acid in phosphate free water and 125 μl of 2% (w/v) sodium 
citrate and 2% (v/v) acetic acid also in phosphate free water were added for colour 
development. The samples were incubated at 37⁰C for 3 hours and the plate was read at 850 
nm with a BioTek microtitre plate reader (USA).  MsHsp70-1 (alfalfa Hsp70-1) and His6-
Hsj1a (kindly donated by Ingrid Cockburn) were readily available in our laboratory and were 
included as controls.  Three independent ATPase assays were performed with triplicate 
measurement for each time point using a fresh batch of purified protein.  
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3.1.  Introduction  
This chapter describes results obtained from the cloning of pQE30-Pfj2, the expression and 
purification of His6-Pfj2, and the effect of His6-Pfj2 on the ATPase activity of mammalian 
His6-BiP.  The recombinant plasmid was generated by inserting the codon-optimised Pfj2 
sequence into a prokaryotic expression vector pQE30.  A BamHI restriction endonuclease 
recognition site was engineered at the 5’ end of Pfj2 coding sequence and KpnI at the 3’ end 
of the sequence.  In order to facilitate production of His6-Pfj2, codon-optimised Pfj2 was 
synthesised for optimal expression in E. coli.  His6-Pfj2 was expressed in E. coli 
M15[pREP4] cells and purified under denaturing conditions using nickel affinity 
chromatography.  Finally, ATPase assays were conducted to determine whether His6-Pfj2 can 
act as a co-chaperone by stimulating the activity of mammalian His6-BiP.  Alfalfa Hsp70-1 
and human His6-Hsj1a were used as controls.  This chapter also presents a bioinformatic 
analysis of Pfj2.  Firstly, a multiple sequence alignment of Pfj2 and other type II Hsp40s 
namely, Saccharomyces cerevisiae Sis1, human Hsj1a and DnaJB4 was carried out to 
identify conserved regions typical of type II Hsp40s such as J-domain and G/F rich region.  
Secondly, a pairwise sequence alignment of Pfj2 with human ERdj5 was generated in order 
to compare domain similarities between the two proteins. Thirdly, the Pfj2 sequence was 
analysed to locate the putative ER signal sequence.  The alignment between database 
obtained Pfj2 and codon-optimised Pfj2 nucleotide sequences was also performed.  Finally, a 
multiple sequence alignment of PfBiP, hamster GRP-78/BiP, Medicago sativa MsHsp70-1 
and S. cerevisiae BiP was generated to determine conserved N- and C-terminal residues 
essential for functional interactions and substrate binding. The methodology employed in 
each experiment was described in the previous chapter.  This chapter present the results 
obtained. 
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3.2.  Bioinformatic analysis of Pfj2 
3.2.1.  Sequence alignment of Pfj2 with typical type II Hsp40s 
The amino acid sequence of Pfj2 was retrieved from the PlasmoDB database.  Other type II 
Hsp40s namely, human ERdj5, S. cerevisiae Sis1, human Hsj1a and human DnaJB4 were 
retrieved from the NCBI database.  A multiple sequence alignment was generated using 
ClustalW to compare domain similarities.  The results are shown in Figure 3.1. 
 
The multiple sequence alignment shows the presence of a J-domain with conserved HPD 
motifs and G/F region typical of type II Hsp40s in the N-terminus of each amino acid 
sequence.  The J-domains are highlighted in grey with HPD motifs highlighted in red.  The 
G/F rich regions are highlighted in turquoise.  The size of Pfj2 is predicted to be 62.3 kDa 
using BioEdit (Hall, 1999) and the number of amino acid residues is 540.  Human Hsj1a is 
the smallest in protein size, 37.8 kDa, and has the smallest number of amino acid, 277.  S. 
cerevisiae Sis1 and human DnaJB4 have very similar protein sizes of 37.5 kDa and 37.8 kDa 
respectively, and the number of amino acid is also similar, 352 and 337 respectively.  ERdj5 
has the biggest protein size of 91.1 kDa and amino acid of 793.  Even though the proteins all 
have different number of amino acids, the percentage identity and similarity presented refers 
to the highlighted J-domain and the G/F region.  The sequence identity and similarity of the 
J-domain and G/F region of Pfj2 with other type II Hsp40s and the predicted protein sizes are 
presented in Table 3.1. 
Table 3.1: Comparison of the J-domain and G/F region of type II Hsp40s sequence identity, 
similarity, size of proteins and number of amino acid residues with Pfj2 
Type II Hsp40s % Identity % Similarity Size (kDa) Number of 
amino acid 
residues 
ERdj5 21 31 91.1 793 
Sis1 27 40 37.5 352 
Hsj1a 32 42 30.6 277 
DnaJB4 30 45 37.8 337 
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Pfj2               MNVTNVVKRRKKLSYFHSLLLIIFSFFLSCARGMDYYKRLGVKRNATKEDISKAYRQLAKEYHPDIAPD----KEKDFIEIANAYETLSDPEKRKMYDMY 96 
ERdj5              MGVWLNKDDYIRDLKRIILCFLIVYMAILVGTDQDFYSLLGVSKTASSREIRQAFKKLALKLHPDKNPNNPN-AHGDFLKINRAYEVLKDEDLRKKYDKY 99 
Sis1               -----------------------------MVKETKLYDLLGVSPSANEQELKKGYRKAALKYHPDKPTG----DTEKFKEISEAFEILNDPQKREIYDQY 67 
Hsj1a              --------------------------------MASYYEILDVPRSASADDIKKAYRRKALQWHPDKNPDNKEFAEKKFKEVAEAYEVLSDKHKREIYDRY 68 
DnaJB4             -----------------------------MGKD--YYCILGIEKGASDEDIKKAYRKQALKFHPDKNKSPQ--AEEKFKEVAEAYEVLSDPKKREIYDQF 67 
 
Pfj2               GEDYAQG--------------GMGGGSPGR---GEHAHGFHFDQDVVNEIFKQFAGGGGAGASGGRAGNFHFKFTSG----------GPSFNHFEDEYED 169 
ERdj5              GEKGLEDNQGGQYESWNYYRYDFGIYDDDPEIITLERREFDAAVNSGELWFVNFYSPGCSHCHDLAPTWRDFAKEVDGLLRIGAVNCGDDRMLCRMKGVN 199 
Sis1               GLEAARSGGPSFGPGGPGGAGGAGGFPGGA---GGFSGGHAFSNEDAFNIFSQFFGGSSPFGG-----------------------------------AD 129 
Hsj1a              GREGLTG-------------TGTGPSRAEA---GSGGPGFTFTFRSPEEVFREFFGSGDPF--------------------------------------- 113 
DnaJB4             GEEGLK--------------GGAGGTDGQG---GTFR--YTFHG-DPHATFAAFFGGSNPF-------------------------------------EI 110 
 
Pfj2               IYKNEVLKINSKNIESVLNDISFSLIINFYSPTC---------------------------------SHCISFKKKYLKLRKKFDGYITFAVVNCQEENM 236 
ERdj5              SYPSLFIFRSGMAAVKYHGDRSKESLVSFAMQHVRSTVTELWTGNFVNSIQTAFAAGIGWLITFCSKGGDCLTSQTRLRLSGMLDGLVNVGWMDCATQDN 299 
Sis1               DSGFSFSSYPSGGGAGMGGMPGGMGGMHGGMGGM---------------------------------PGGFRSASSSPTYPEEETVQVNLPVS------- 189 
Hsj1a              --------------AELFDDLGPFSELQN---------------------------------------RGSRHSGPFFTFSSSFPGHSDFSSS------- 153 
DnaJB4             FFGRRMGGGRDSEEMEIDGDP--FSAFGFSMNGY---------------------------------PRDRNSVGPS-RLKQDPPVIHELRVS------- 167 
 
Pfj2               LCRKYNVKS------LPQLILMRSDKTYETFYGNRTDENLTYFIKNNIPSAIIECNNQKKLDNFLTQNIEIPKVLFFISHNDNIVMLKALSLE------- 323 
ERdj5              LCKSLDITTSTTAYFPPGATLNNKEKNSILFLNSLDAKEIYLEVIHNLPDFELLSAKRVKDRLAHHRWLLFFHFGKNENSNDPELKKLKTLLKNDHIQVG 399 
Sis1               -LEDLFVGK------KKSFKIGRK-----GPHGASEKTQIDIQLKPGWKAGTKITYKNQGDYNPQTG--------------------------------- 244 
Hsj1a              -SFSFSPG---------------------------AGAFRSVSTSTTFVQGRRITTRR------------------------------------------ 183 
DnaJB4             -LEEIYSGC------TKRMKISRKRLNADGRSYRSEDKILTIEIKKGWKEGTKITFPREGDETPNS---------------------------------- 226 
 
Pfj2               --------------FKKRINIGIIYNTNYSVMKLFKKKNIKTPSLLLVDDIDSLSGDLTQLKNFDFN---------------ILSLKLSHIVAQNRLKNN 394 
ERdj5              RFDCSSAPDICSNLYVFQPSLAVFKGQGTKEYEIHHGKKILYDILAFAKESVNSHVTTLGPQNFPANDKEPWLVDFFAPWCPPCRALLPELRRASNLLYG 499 
Sis1               ---------------RRKTLQFVIQEKSHPNFKRDGDDLIYTLPLSFKESLLGFS--------------------------------------------- 284 
Hsj1a              -----------------------IMENGQERVEVEEDGQLKSVTINGVPDDLARG--------------------------------------------- 215 
DnaJB4             ---------------IPADIVFIIKDKDHPKFKRDGSNIIYTAKISLREALCGCS--------------------------------------------- 266 
 
Pfj2               LYGHVTSYQELTKKKYESGQCHEKDSQICFFILKLLKKNYKSFDEDIKKVANKFSSDPLKILYINIYQQPYILDSF------GLSNNIQYSNGLILVAFR 488 
ERdj5              QLKFGTLDCTVHEGLCNMYNIQAYPTTVVFNQSNIHEYEGHHSAEQILEFIEDLMNPSVVSLTPTTFNELVTQRKHNEVWMVDFYSPWCHPCQVLMPEWK 599 
Sis1               --------------------------------KTIQTIDGRTLPLSRVQPVQPSQTSTYPGQGMPTPKNPSQRGNL------IVKYKVDYPISLNDAQKR 346 
Hsj1a              --------------------------------LELSRREQQPSVTSRSGGTQVQQTP------ASCPLDSDLSEDE------DLQLAMAYSLSEMEAAGK 271 
DnaJB4             --------------------------------INVPTLDGRNIPMSVNDIVKPGMRRRIIGYGLPFPKNPDQRGDL------LIEFEVSFPDTISSSSKE 328 
 
Pfj2               PKRQKFK--VYDGDVNVENVHKFVDNVVSGGIPINQNIKRSLKFVHVEQYDDEL---------------------------------------------- 540 
ERdj5              RMARTLTGLINVGSIDCQQYHSFCAQENVQRYPEIRFFPPKSNKAYHYHSYNGWNRDAYSLRIWGLGFLPQVSTDLTPQTFSEKVLQGKNHWVIDFYAPW 699 
Sis1               AIDENF---------------------------------------------------------------------------------------------- 352 
Hsj1a              KPADVF---------------------------------------------------------------------------------------------- 277 
DnaJB4             VLRKHLP--AS----------------------------------------------------------------------------------------- 337 
 
Pfj2               ---------------------------------------------------------------------------------------------- 540 
ERdj5              CGPCQNFAPEFELLARMIKGKVKAGKVDCQAYAQTCQKAGIRAYPTVKFYFYERAKRNFQEEQINTRDAKAIAALISEKLETLRNQGKRNKDEL 793 
Sis1               ---------------------------------------------------------------------------------------------- 352 
Hsj1a              ---------------------------------------------------------------------------------------------- 277 
DnaJB4             ---------------------------------------------------------------------------------------------- 337 
 
Figure 3.1:  Multiple sequence alignment of the amino acid sequence of Pfj2 with typical type II Hsp40s.  The J-domains are highlighted in grey with conserved HPD motifs highlighted in red.  The G/F regions 
are highlighted in turquoise. Pfj2 (locus: PF11_ _0099), ERdj5 (accession: AAN73271.1), Sis1 (accession: CAA95866.1), Hsj1a (accession: AAA09034.1) and DnaJB4 (accession: NP_008965.2). 
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3.2.2.  Sequence alignment of Pfj2 with human ERdj5 
The amino acid sequence of Pfj2 was obtained from the PlasmoDB database and human 
ERdj5 was retrieved from the NCBI database. Pairwise sequence alignment was generated 
using ClustalW to identify domain similarities and identities.  The results are shown in Figure 
3.2. 
 
The percentage identity and similarity of Pfj2 and ERdj5 were calculated as 14% and 26% 
respectively.  Although the proteins are not highly conserved and are of different sizes, each 
amino acid sequence contains a J domain and conserved HPD motif in the N-terminal region.  
The J-domains are highlighted in grey and HPD motifs are highlighted in red.  A G/F region 
is identified in both sequences at the N-terminus and is highlighted in turquoise.  
Furthermore, CXYC-variant motif signifying thioredoxin-like domains are present in both 
sequences and are highlighted in yellow.  ER-retention motifs are highlighted in green and 
are represented by DDEL in Pfj2 and KDEL in ERdj5 at the C-terminus of the protein.  This 
analysis also showed the presence of a putative PEXEL motif represented by RQLAK and 
highlighted violet in the amino acid sequence of Pfj2.  As expected, a PEXEL motif was 
absent in the amino acid sequence of ERdj5.  Putative ER signal sequences are highlighted in 
pink in the N-terminal regions of Pfj2 and ERdj5.  The predicted protein sizes and number of 
amino acid residues of Pfj2 and ERdj5 are presented in Table 3.1 in section 3.2.1.   
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Pfj2               MNVTNVVKRRKKLSYFHSLLLIIFSFFLSCARG--MDYYKRLGVKRNATKEDISKAYRQLAKEYHPDIAPDK---EKDFIEIANAYETLSDPEKRKMYDM 95   
ERdj5              --MGVWLNKDDYIRDLKRIILCFLIVYMAILVGTDQDFYSLLGVSKTASSREIRQAFKKLALKLHPDKNPNNPNAHGDFLKINRAYEVLKDEDLRKKYDK 98   
 
Pfj2               YGEDYAQGGMGGGSPGRGEHAHGFHFDQD---VVNEIFKQFAGGGGAG------------------------------------------------ASGG 144  
ERdj5              YGEKGLEDNQGGQYESWNYYRYDFGIYDDDPEIITLERREFDAAVNSGELWFVNFYSPGCSHCHDLAPTWRDFAKEVDGLLRIGAVNCGDDRMLCRMKGV 198  
 
Pfj2               RAGNFHFKFTSGGPSFNHFEDEYEDIYKNEVLKINSKNIESVLNDISFSLIINFYSPTCSHCISFKKK---------YLKLRKKFDGYITFAVVNCQEEN 235  
ERdj5              NSYPSLFIFRSGMAAVKYHGDRSKESLVSFAMQHVRSTVTELWTGNFVNSIQTAFAAGIGWLITFCSKGGDCLTSQTRLRLSGMLDGLVNVGWMDCATQD 298  
 
Pfj2               MLCRKYNVKS------LPQLILMRSDKTYETFYGNRTDENLTYFIKNNIPSAIIECNNQKKLDNFLTQNIEIPKVLFFISHNDNIVMLKALSLEFKKRIN 329  
ERdj5              NLCKSLDITTSTTAYFPPGATLNNKEKNSILFLNSLDAKEIYLEVIHNLP--DFELLSAKRVKDRLAHHRWLLFFHFGKNENSNDPELKKLKTLLKN-DH 395  
 
Pfj2               IGIIYNTNYSVMKLFKKKNIKTPSLLLVDDIDSLSGDLTQLKNFDFNILSLKLSHIVAQN------------------------------------RLKN 393  
ERdj5              IQVGRFDCSSAPDICSNLYVFQPSLAVFKGQGTKEYEIHHGKKILYDILAFAKESVNSHVTTLGPQNFPANDKEPWLVDFFAPWCPPCRALLPELRRASN 495  
                            
Pfj2               NLYGHVTS----------------------YQELTKKKYESGQCHEKDSQICFFILKLLKKNYKSFD--------------------------------- 438  
ERdj5              LLYGQLKFGTLDCTVHEGLCNMYNIQAYPTTVVFNQSNIHEYEGHHSAEQILEFIEDLMNPSVVSLTPTTFNELVTQRKHNEVWMVDFYSPWCHPCQVLM 595  
 
Pfj2               EDIKKVANKFS--------------------------------SDPLKILYINIY----QQPYILDSFGLSNNIQYSNGLILVAFRPKRQ---------- 492  
ERdj5              PEWKRMARTLTGLINVGSIDCQQYHSFCAQENVQRYPEIRFFPPKSNKAYHYHSYNGWNRDAYSLRIWGLGFLPQVSTDLTPQTFSEKVLQGKNHWVIDF 695  
 
Pfj2               ----------------------KFKVYDGDVNVENVHKFVDNVVSGGIP-----INQNIKRSLKFVHVEQYDDEL----------------------- 540  
ERdj5              YAPWCGPCQNFAPEFELLARMIKGKVKAGKVDCQAYAQTCQKAGIRAYPTVKFYFYERAKRNFQEEQINTRDAKAIAALISEKLETLRNQGKRNKDEL 793  
 
Figure 3.2:  Pairwise alignment of the amino acid sequence of Pfj2 and ERdj5. The putative Pfj2 ER signal sequence is highlighted in pink. The J-
domains are highlighted in grey with HDP motifs highlighted in red.  Putative Pfj2 PEXEL motif is highlighted in violet. The G/F rich regions are highlighted 
in turquoise and thioredoxin-like domains in yellow.  The ER retention motifs for Pfj2 and ERdj5 are highlighted in green respectively.  Pfj2 (locus: PF11_ 
_0099) and ERdj5 (accession: AAN73271.1). 
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3.2.3.  Signal prediction of Pfj2 
The putative ER signal sequence of Pfj2 was identified using Phobius (Käll et al., 2007) 
(Refer to section 2.2.2).  The Phobius server is used for the prediction of signal peptides from 
the amino acid sequence of a protein.  The results are shown in Figure 3.3. 
 
The predicted signal sequence of Pfj2 is represented by the red line in the N-terminal region 
of the amino acid sequence.  The blue and green lines represent the non cytoplasmic and 
cytoplasmic regions respectively.  A predicted transmembrane domain is not evident in the 
analysis. 
 
                  
 
 
 
 
 
 
 
 
 
Figure 3.3:  Prediction of a putative signal sequence of Pfj2.  Red: Predicted signal peptide; Blue: 
Non cytoplasmic domain; Green: Cytoplasmic domain.   
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3.2.4.  Sequence alignment of Hsp70s 
The amino acid sequence of PfBiP was retrieved from PlasmoDB.  Hamster GRP-78 and S. 
cerevisiae BiP (Sis1BiP) were obtained from NCBI.  Medicago sativa Hsp70 (MsHsp70-1) was 
obtained from EMBL-EBI.  A multiple sequence alignment was generated using ClustalW to 
determine conserved residues in the N- and C-terminal domains that are essential for 
functional interactions and substrate binding. The results are shown in Figure 3.4.   
 
Multiple sequence alignment showed highly conserved amino acid residues in the N-terminal 
domain of the Hsp70s.  These include phosphate binding sites highlighted in turquoise, 
connecting regions highlighted in red and adenosine regions highlighted in grey.  The C-
terminal consists of ß-subdomain highlighted in green that forms a hydrophobic substrate 
compartment which accommodates peptide substrate (Mayer et al., 1998).  Highlighted in 
pink is the α-helical subdomain essential for substrate binding (Mayer et al., 1998).  The size 
of PfBiP is predicted to be 72.3 kDa using BioEdit (Hall, 1999) and the number of amino 
acid residues is 652.  The hamster GRP-78, Sis1BiP and MsHsp70-1 have very similar 
protein sizes of 72.3 kDa, 74.4 kDa and 70.9 kDa respectively.  The number of amino acid of 
these proteins is also similar and is 654, 682 and 649 respectively.  The overall sequence 
identity and similarity of PfBiP and other Hsp70s and the predicted protein sizes are 
presented in Table 3.2. 
Table 3.2:  Comparison of Hsp70s sequence identity, similarity, size of proteins and number 
of amino acid residues with PfBiP 
Hsp70s % Identity % Similarity Size (kDa) Number of 
amino acid 
residue  
GRP-78 64 78 72.3 654 
Sis1BiP 73 57 74.4 682 
MsHsp70-1 72 55 70.9 649 
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PfBiP              -----------MKQIRPYILLLIVSLLKFIS-----------AVDSNIEGPVIGIDLGTTYSCVGVFKNGRVEILNNELGNRITPSYVSFVD-GERKVGE 77   
GRP-78             -----------MKFPMVAAALLLLCAVRAEE-----------EDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGD 78   
Sis1BiP            MFFNRLSAGKLLVPLSVVLYALFVVILPLQNSFHSSNVLVRGADDVENYGTVIGIDLGTTYSCVAVMKNGKTEILANEQGNRITPSYVAFTD-DERLIGD 99   
MsHsp70-1          -------------------------------------------MAGKGEGPAIGIDLGTTYSCVGVWQHDRVEIIANDQGNRTTPSYVAFTD-SERLIGD 56   
 
PfBiP              AAKLEATLHPTQTVFDVKRLIGRKFDDQEVVKDRSLLPYEIVNNQG-KPNIKVQIKD-KDTTFAPEQISAMVLEKMKEIAQSFLGKPVKNAVVTVPAYFN 175  
GRP-78             AAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKT-KPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFN 177  
Sis1BiP            AAKNQVAANPQNTIFDIKRLIGLKYNDRSVQKDIKHLPFNVVNKDG-KPAVEVSVKG-EKKVFTPEEISGMILGKMKQIAEDYLGTKVTHAVVTVPAYFN 197  
MsHsp70-1          AAKNQVAMNPTNTVFDAKRLIGRRISDASVQSDMKLWPFKVTAGPGEKPMIGVNYKG-EEKLFASEEISSMVLIKMREIAEAYLGVTIKNAVVTVPAYFN 155  
 
PfBiP              DAQRQATKDAGTIAGLNIVRIINEPTAAALAYGLDKKE----ETSILVYDLGGGTFDVSILVIDNGVFEVYATAGNTHLGGEDFDQRVMDYFIKMFKKKN 271  
GRP-78             DAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREG---EKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKT 274  
Sis1BiP            DAQRQATKDAGTIAGLNVLRIVNEPTAAAIAYGLDKSDK---EHQIIVYDLGGGTFDVSLLSIENGVFEVQATSGDTHLGGEDFDYKIVRQLIKAFKKKH 294  
MsHsp70-1          DSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDKKATSVGEKNVLIFDLGGGTFDVSLLTIEEGIFEVKATAGDTHLGGEDFDNRMVNHFVQEFKRKN 255  
 
PfBiP              NIDLRTDKRAIQKLRKEVEIAKRNLSVVHSTQIEIEDIVEGHNFSETLTRAKFEELNDDLFRETLEPVKKVLDDAKYEKSKIDEIVLVGGSTRIPKIQQI 371  
GRP-78             GKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFFEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQL 374  
Sis1BiP            GIDVSDNNKALAKLKREAEKAKRALSSQMSTRIEIDSFVDGIDLSETLTRAKFEELNLDLFKKTLKPVEKVLQDSGLEKKDVDDIVLVGGSTRIPKVQQL 394  
MsHsp70-1          KKDISGNPRALRRLRTACERAKRTLSSTAQTTIEIDSLFEGVDFYTTITRARFEELNMDLFRKCMEPVEKCLRDAKMDKSTVHDVVLVGGSTRIPKVQQL 355  
 
PfBiP              IKEFFNGKEPNRGINPDEAVAYGAAIQAGIILG---EELQDVVLLDVTPLTLGIETVGGIMTQLIKRNTVIPTKKSQTFSTYQDNQPAVLIQVFEGERAL 468  
GRP-78             VKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGD--QDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPL 472  
Sis1BiP            LESYFDGKKASKGINPDEAVAYGAAVQAGVLSGE--EGVEDIVLLDVNALTLGIETTGGVMTPLIKRNTAIPTKKSQIFSTAVDNQPTVMIKVYEGERAM 492  
MsHsp70-1          LQDFFNGKELCKSINPDEAVAYGAAVQAAILSGEGNEKVQDLLLLDVTPLSQGLETAGGVMTVLIPRNTTIPTKKEQVFSTYSDNQPGVLIQVYEGERTR 455  
 
PfBiP              TKDNHLLGKFELSGIPPAQRGVPKIEVTFTVDKNGILHVEAEDKGTGKSRGITITNDKGRLSKEQIEKMINDAEKFADEDKNLREKVEAKNNLDNYIQSM 568  
GRP-78             TKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSL 572  
Sis1BiP            SKDNNLLGKFELTGIPPAPRGVPQIEVTFALDANGILKVSATDKGTGKSESITITNDKGRLTQEEIDRMVEEAEKFASEDASIKAKVESRNKLENYAHSL 592  
MsHsp70-1          TKDNNLLGKFELSGIPPAPRGVPQITVCFDIDANGILNVSAEDKTTGQKNKITITNDKGRLSKEEIEKMVQEAEKYKSEDEEHKKKVEAKNSLENYAYNM 555  
 
PfBiP              KATVEDKDKLADKIEKEDKNTILSAVKDAEDWLNNNSN-ADSEALKQKLKDLEAVCQPIIVKLYGQPGGPSPQPSGDED---VDS-------DEL- 652  
GRP-78             KNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQD-ADIEDFKAKKKELEEIVQPIISKLYGSAG---PPPTGEED---TSEK------DEL- 654  
Sis1BiP            KNQVNG--DLGEKLEEEDKETLLDAANDVLEWLDDNFETAIAEDFDEKFESLSKVAYPITSKLYGGADGSGAADYDDED---EDDDGDYFEHDEL- 682  
MsHsp70-1          RNTIKD-EKISSKLSGGDKKQIEDAIEGAIQWLDANQL-AEADEFEDKMKELETICNPIIAKMYQGGAGEGPEVDDDAAPPPSGSGGAGPKIEEVD 649  
 
 
Figure 3.4:  Multiple sequence alignment of various Hsp70s.  Turquoise highlighted regions represent phosphate binding sites. The connecting regions are 
shaded in red.  Adenosine phosphate binding region are highlighted in grey.  Highlighted in green is the ß-subdomain and in pink is the α-helical subdomain.  
PfBiP (Locus: PFI0875), GRP-78 (Accession: P07823.1), Sis1BiP (Accession: EDN63302.1) and MsHsp70-1 (EMBL-Bank CDS: AAV98051).
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3.3.  Codon optimisation of Pfj2 
Codon optimisation is a technique used to increase protein expression levels by increasing the translational efficiency of the gene of interest.  
This technique involves alteration of rare codons in the gene of interest to those used more frequently by the host.   
pUC57-Pfj2 which contains the full-length codon-optimised Pfj2 coding sequence in pUC57 was obtained from GenScript.  The nucleotide 
sequence of Pfj2 obtained from PlasmoDB (Locus: PF11_0099) and codon-optimised Pfj2 was translated into amino acid using ApE 2.0.39.  
The results are shown in Figure 3.5. 
Nucleotide sequences are arranged in codons and corresponding 1-letter amino acid codes are presented below each codon.  The nucleotide 
sequences are numbered.  Although the nucleotide sequences of the database obtained Pfj2 and codon-optimised Pfj2 are different (highlighted 
in yellow), both nucleotide sequences encode the same protein. 
               1                   60 
Optimised      ATG GAT TAT TAC AAA CGT CTG GGC GTG AAA CGC AAT GCG ACC AAA GAA GAT ATT TCT AAA  
Database       ATG GAT TAT TAC AAA AGA CTG GGC GTT AAA CGG AAC GCC ACA AAA GAA GAT ATT TCA AAA 
                M   D   Y   Y   K   R   L   G   V   K   R   N   A   T   K   E   D   I   S   K 
               61              120 
Optimised  GCC TAC CGC CAG CTG GCA AAA GAA TAT CAT CCG GAT ATC GCC CCG GAT AAA GAA AAA GAT 
Database GCT TAT AGG CAG CTA GCT AAA GAA TAT CAT CCA GAT ATA GCG CCC GAC AAA GAA AAA GAT 
     A   Y   R   Q   L   A   K   E   Y   H   P   D   I   A   P   D   K   E   K   D 
               121              180 
Optimised   TTC ATC GAA ATC GCG AAC GCC TAC GAA ACG CTG AGC GAT CCG GAA AAA CGT AAA ATG TAC  
Database  TTT ATA GAA ATT GCA AAC GCC TAT GAA ACG TTA TCA GAT CCT GAG AAA AGA AAA ATG TAT 
     F   I   E   I   A   N   A   Y   E   T   L   S   D   P   E   K   R   K   M   Y 
               181               240 
Optimised  GAT ATG TAC GGT GAA GAT TAT GCG CAG GGC GGT ATG GGC GGT GGC TCT CCG GGT CGC GGC  
Database   GAT ATG TAT GGT GAG GAC TAT GCC CAA GGA GGT ATG GGA GGA GGA AGT CCC GGG AGA GGG 
      D   M   Y   G   E   D   Y   A   Q   G   G   M   G   G   G   S   P   G   R   G 
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               241              300 
Optimised   GAA CAT GCA CAC GGC TTT CAC TTC GAT CAG GAT GTG GTT AAT GAA ATC TTC AAA CAG TTC 
Database   GAA CAT GCA CAT GGT TTT CAT TTT GAT CAA GAT GTA GTA AAT GAA ATA TTT AAA CAA TTT  
     E   H   A   H   G   F   H   F   D   Q   D   V   V   N   E   I   F   K   Q   F            
 
 
               301              360 
Optimised  GCG GGT GGC GGT GGC GCA GGT GCC AGC GGT GGC CGT GCG GGT AAC TTT CAT TTC AAA TTT  
Database  GCA GGA GGT GGT GGT GCG GGT GCG AGT GGT GGT AGA GCG GGG AAT TTT CAT TTT AAA TTT 
       A   G   G   G   G   A   G   A   S   G   G   R   A   G   N   F   H   F   K   F   
 
      361               420 
Optimised   ACC AGC GGT GGC CCG TCT TTC AAC CAC TTC GAA GAT GAA TAC GAA GAT ATT TAC AAA AAC 
Database  ACA TCT GGT GGT CCT AGT TTT AAT CAT TTT GAA GAT GAA TAT GAA GAT ATA TAT AAA AAT 
      T   S   G   G   P   S   F   N   H   F   E   D   E   Y   E   D   I   Y   K   N 
               421               480 
Optimised   GAA GTG CTG AAA ATC AAC AGC AAA AAC ATC GAA TCT GTT CTG AAC GAT ATC AGT TTC AGC 
Database  GAA GTT TTA AAA ATA AAT TCT AAG AAT ATT GAA TCT GTT TTA AAT GAC ATA TCA TTT TCT 
     E   V   L   K   I   N   S   K   N   I   E   S   V   L   N   D   I   S   F   S 
 
               481              540 
Optimised   CTG ATC ATC AAC TTC TAT AGT CCG ACC TGC AGC CAT TGT ATC TCT TTC AAG AAA AAA TAC 
Database       TTA ATA ATA AAT TTT TAT TCA CCT ACA TGT TCT CAT TGT ATA TCT TTT AAA AAG AAA TAT  
     L   I   I   N   F   Y   S   P   T   C   S   H   C   I   S   F   K   K   K   Y 
 
     541                600 
Optimised   CTG AAA CTG CGT AAA AAA TTC GAT GGT TAC ATC ACG TTC GCA GTG GTT AAC TGC CAG GAA 
Database   TTA AAA TTA CGT AAG AAA TTT GAT GGA TAT ATA ACA TTT GCT GTT GTA AAT TGT CAA GAG 
     L   K   L   R   K   K   F   D   G   Y   I   T   F   A   V   V   N   C   Q   E 
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    601                660 
Optimised   GAA AAC ATG CTG TGT CGC AAA TAC AAC GTT AAA TCT CTG CCG CAG CTG ATT CTG ATG CGT 
Database   GAA AAT ATG TTG TGT AGA AAA TAT AAT GTA AAA TCC TTA CCA CAA TTA ATA TTA ATG AGA  
     E   N   M   L   C   R   K   Y   N   V   K   S   L   P   Q   L   I   L   M   R 
 
    661                720 
Optimised  AGT GAT AAA ACC TAT GAA ACG TTC TAC GGC AAC CGC ACC GAT GAA AAC CTG ACG TAC TTC 
Database   TCT GAT AAA ACA TAT GAA ACA TTT TAT GGT AAT AGA ACT GAT GAG AAT TTA ACT TAT TTT  
     S   D   K   T   Y   E   T   F   Y   G   N   R   T   D   E   N   L   T   Y   F   
 
               721                                      780 
Optimised  ATC AAA AAC AAC ATC CCG AGC GCG ATT ATC GAA TGC AAC AAT CAG AAA AAA CTG GAT AAC 
Database  ATA AAG AAT AAT ATT CCG TCT GCA ATT ATT GAA TGT AAT AAT CAG AAA AAG TTA GAT AAT  
       I   K   N   N   I   P   S   A   I   I   E   C   N   N   Q   K   K   L   D   N   
 
               781                840 
Optimised   TTT CTG ACC CAG AAT ATT GAA ATC CCG AAA GTG CTG TTT TTC ATT AGC CAC AAC GAT AAT 
Database  TTT TTA ACA CAA AAT ATA GAA ATA CCT AAG GTG CTT TTT TTT ATA TCG CAT AAC GAT AAT  
     F   L   T   Q   N   I   E   I   P   K   V   L   F   F   I   S   H   N   D   N   
 
               841                900 
Optimised  ATC GTT ATG CTG AAA GCC CTG TCT CTG GAA TTC AAA AAA CGT ATC AAC ATC GGT ATC ATC 
Database   ATC GTT ATG TTA AAA GCA TTA TCT CTG GAA TTT AAG AAG AGA ATA AAT ATT GGT ATA ATA  
     I   V   M   L   K   A   L   S   L   E   F   K   K   R   I   N   I   G   I   I 
 
               901                960 
Optimised   TAC AAC ACC AAC TAC TCT GTG ATG AAA CTG TTC AAA AAG AAA AAC ATC AAA ACG CCG AGT 
Database  TAT AAT ACA AAT TAT AGT GTC ATG AAA TTA TTT AAG AAA AAA AAT ATA AAG ACA CCA TCT 
     Y   N   T   N   Y   S   V   M   K   L   F   K   K   K   N   I   K   T   P   S   
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               961                1020 
Optimised   CTG CTG CTG GTT GAT GAT ATC GAT TCT CTG AGT GGC GAT CTG ACC CAG CTG AAA AAC TTC 
Database  TTA TTA CTT GTC GAT GAT ATT GAT AGT TTA TCA GGG GAT TTA ACA CAA TTA AAA AAT TTC  
       L   L   L   V   D   D   I   D   S   L   S   G   D   L   T   Q   L   K   N   F   
 
 
               1021               1080 
Optimised   GAT TTC AAC ATC CTG AGT CTG AAA CTG AGC CAT ATC GTG GCG CAG AAC CGC CTG AAA AAC 
Database   GAT TTT AAT ATT TTG TCA TTA AAA TTA AGT CAC ATT GTT GCA CAA AAT AGA TTA AAA AAT  
     D   F   N   I   L   S   L   K   L   S   H   I   V   A   Q   N   R   L   K   N   
 
               1081               1140 
Optimised   AAT CTG TAC GGT CAC GTT ACC AGT TAT CAG GAA CTG ACC AAG AAA AAA TAC GAA AGT GGC 
Database AAT TTA TAT GGA CAT GTA ACA TCT TAC CAA GAA TTA ACC AAA AAA AAA TAT GAA TCG GGA  
     N   L   Y   G   H   V   T   S   Y   Q   E   L   T   K   K   K   Y   E   S   G   
 
               1141                1200 
Optimised   CAG TGC CAT GAA AAA GAT AGC CAG ATT TGC TTT TTC ATC CTG AAA CTG CTG AAG AAA AAC 
Database  CAA TGT CAT GAG AAG GAT TCA CAA ATA TGT TTC TTT ATT TTA AAA TTA TTA AAA AAA AAT  
      Q   C   H   E   K   D   S   Q   I   C   F   F   I   L   K   L   L   K   K   N  
  
    1201               1260 
Optimised   TAT AAA AGC TTC GAT GAA GAT ATC AAA AAA GTG GCA AAC AAA TTC AGC TCT GAT CCG CTG 
Database   TAT AAA TCA TTT GAT GAA GAT ATT AAA AAG GTA GCA AAC AAA TTC TCA AGT GAC CCC TTA  
      Y   K   S   F   D   E   D   I   K   K   V   A   N   K   F   S   S   D   P   L   
 
               1261               1320 
Optimised  AAA ATT CTG TAT ATT AAC ATC TAC CAG CAG CCG TAT ATC CTG GAT TCT TTT GGT CTG AGT 
Database  AAA ATT TTA TAT ATT AAT ATA TAT CAA CAA CCA TAT ATA TTA GAT TCT TTT GGA CTA TCG  
      K   I   L   Y   I   N   I   Y   Q   Q   P   Y   I   L   D   S   F   G   L   S 
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               1321               1380 
Optimised   AAC AAT ATT CAG TAC AGC AAT GGC CTG ATC CTG GTG GCG TTC CGT CCG AAA CGC CAG AAA 
Database   AAT AAT ATT CAA TAT TCA AAT GGT TTA ATC TTG GTT GCC TTT AGA CCA AAG AGA CAA AAA  
     N   N   I   Q   Y   S   N   G   L   I   L   V   A   F   R   P   K   R   Q   K 
 
               1381               1440 
Optimised  TTT AAA GTT TAT GAT GGC GAT GTG AAC GTT GAA AAT GTG CAT AAA TTC GTT GAT AAC GTT 
Database  TTT AAA GTA TAC GAT GGT GAT GTA AAT GTT GAA AAT GTT CAT AAA TTT GTT GAT AAT GTG  
       F   K   V   Y   D   G   D   V   N   V   E   N   V   H   K   F   V   D   N   V 
 
               1441               1500 
Optimised  GTT AGT GGT GGC ATT CCG ATC AAC CAG AAT ATT AAA CGC AGC CTG AAA TTT GTG CAC GTT 
Database   GTT AGT GGG GGT ATA CCA ATA AAT CAA AAT ATA AAG AGA AGT CTA AAG TTT GTG CAT GTT  
      V   S   G   G   I   P   I   N   Q   N   I   K   R   S   L   K   F   V   H   V 
 
               1501 
Optimised   GAA CAG TAT GAT GAT GAA CTG  
Database GAG CAA TAT GAT GAT GAA TTG        
     E   Q   Y   D   D   E   L 
Figure 3.5.  The nucleotide sequence and predicted amino acid sequence alignment of the database obtained Pfj2 and codon-optimised Pfj2.  
Different nucleotides are highlighted in yellow.
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3.4.  Cloning of Pfj2 
3.4.1.  Confirmation of pUC57-Pfj2 
The codon-optimised Pfj2 was cloned into pUC57 by GenScript and supplied as a pUC57-Pfj2. 
The pUC57-Pfj2 had essential features including lacZ, rep (pMB1) and the ampicillin resistance 
gene (AmpR).  A schematic diagram of pUC57-Pfj2 which is 4228 bp in size is shown in Figure 
3.6A. 
pUC57-Pfj2 was restricted with BamHI and KpnI and the digest was analysed by agarose gel 
electrophoresis.  The results are shown in Figure 3.6B.  Undigested pUC57-Pfj2 is present in 
lane 1.  Lanes 2 and 3 contain linearised pUC57-Pfj2 restricted with BamHI and KpnI 
respectively.  Three prominent bands were present in lane 4 which contains partially digested 
pUC57-Pfj2 restricted with BamHI and KpnI.  The top band represents linearised pUC57-Pfj2 
restricted once at 4228 bp, the middle band shows linearised pUC57 at 2683 bp and the lower 
band shows linearised Pfj2 coding sequence at 1545 bp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Restriction of pUC57-Pfj2.  (A) Plasmid map of pUC57-Pfj2.  (B) Lane M: λ PstI molecular 
marker; Lane 1:  Undigested pUC57-Pfj2; Lane 2: pUC57-Pfj2 restricted with BamHI; Lane 3: pUC57-
Pfj2 restricted with KpnI; Lane 4: pUC57-Pfj2 restricted with BamHI and KpnI.  
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3.4.2.  Ligation of Pfj2 into pQE30 and verification of pQE30-Pfj2 
The 1545 bp band representing the codon-optimsed Pfj2 sequence was excised from the gel and 
purified before ligation into pQE30.  The Pfj2 coding region was ligated downstream of the His6-
tag sequence.  Important features of the 3443 bp pQE30 vector include the IPTG-inducible T5 
promoter which facilitates high level expression of His6-tagged proteins through recognition by 
RNA polymerase in E. coli.  The vector encodes lac operator sequences (lac O) that allows for 
efficient repression of T5 promoter.  A his6 sequence facilitates purification of recombinant 
protein by nickel affinity chromatography. A ß-lactamase gene encoding ampicillin resistance 
(AmpR) is present to enable specific gene selection.  The pQE30 vector has multiple cloning sites 
(MSC) which contains restriction sites that are commonly used in molecular cloning (Figure 
3.7A) (QIAexpress® The Complete System for 6xHis Technology).   A schematic diagram of 
pQE30-Pfj2 is shown in Figure 3.7A. 
The integrity of pQE30-Pfj2 was confirmed by digestion with BamHI and KpnI followed by 
agarose gel electrophoresis. The results are shown in Figure 3.7C.  Lane 1 contains undigested 
pQE30-Pfj2.  Lane 2 is linearised pQE30 restricted with BamHI at 3443 bp.  Lane 3 contains 
pQE30-Pfj2 restricted with BamHI and KpnI.  The double restriction resulted in linearised 
pQE30 at 3443 bp and the Pfj2 coding sequence at 1545 bp.  
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Figure 3.7: Confirmation of pQE30-Pfj2.  (A) Multiple cloning site of pQE30.  (B) Plasmid map of 
pQE30-Pfj2.  (C) Lane M: λ PstI molecular marker; Lane 1: Undigested pQE30-Pfj2; Lane 2: pQE30 
restricted with BamHI; Lane 3: pQE30-Pfj2 restricted with BamHI and KpnI. 
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3.4.3.  Sequencing of pQE30-Pfj2 
To further verify pQE30-Pfj2, the plasmid was subjected to DNA sequencing as described in 
section 2.3.6.  Approximately 400 bps of readable sequence was obtained using forward and 
reverse primers, therefore, the entire sequence was not obtained.  Furthermore, the frame-shift 
mutation detected hereafter may have interfered with protein folding and function.  The results 
are shown in Figure 3.8. 
Figure 3.8 shows the position of a start codon, ATG, highlighted in turquoise at the 5’end of the 
nucleotide sequence.  Located downstream of the ATG, is the His6-tag sequence highlighted in 
yellow. GCA, highlighted in teal represents the first codon of the Pfj2 coding sequence.  The ER 
signal sequence has been deleted from the Pfj2 coding sequence, therefore, the gene sequence is 
incomplete with a start codon of GCA instead of ATG.  The three dashes ( _ _ _ ) represent the 
missing internal region of the nucleotide sequence.  The stop codon, TAA, is indicated in green 
upstream of the KpnI restriction site, highlighted in pink at the 3’end of the nucleotide sequence.  
DNA sequencing of pQE30-Pfj2 showed the presence of two BamHI sites downstream of the 
His6-tag highlighted in grey and red respectively.  This result was unexpected because only one 
BamHI restriction site was engineered in the 5’ end of the nucleotide sequence.  This additional 
BamHI site generated a frame-shift in the codon-optimised Pfj2 coding sequence resulting in an 
incorrect open reading frame.  
5'TAGAAATCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCAATTG
TGAGCGGATAACAATTTCACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGAGGATC
GCATCACCATCACCATCACGGATCCGATCCAATGGATCCGCATGCGCACGTGGTATGGATTA
TTACAAACGTCTGGGCGTGAAACGCAATGCGACCAAAGAAGATATTTCTAAAGCCTACCGC
CAGCTGGCAAAAGAATATCATCCGGATATCGCCCCGGGATAAAGAAAAAGATTTCATCGAA
ATCGCGAACGCCTACGAAACGCTGAGCGATCCGGAAAAACGTAAAATGTACGATATGTACG
GTGAAGATTATGCGCAGG_ _  _GTCACGTTACCAGTTATCAGGAACTGACCAAGAAAAAATA 
CGAAAGTGGCCAGTGCCATGAAAAAGATAGCCAGATTTGCTTTTTCATCCTGAAACTGCTGA
AGAAAAACTATAAAAGCTTCGATGAAGATATCAAAAAAGTGGCAAACAAATTCAGCTCTGA
TCCGCTGAAAATTCTGTATATTAACATCTACCAGCAGCCGTATATCCTGGATTCTTTTGGTCT
GAGTAACAATATTCAGTACAGCAATGGCCTGATCCTGGTGGCGTTCCGTCCGAAACGCCAGA
AATTTAAAGTTTATGATGGCGATGTGAACGTTGAAAATGTGCATAAATTCGTTGATAACGTT
GTTAGTGGTGGCATTCCGATCAACCAGAATATTAAACGCAGCCTGAAATTTGTGCACGTTGA
ACAGTATGATGATGAACTGTAAGGTACCCCGGGTCGACCTGCAGCC'3 
Figure 3.8:  Nucleotide sequence of pQE30-Pfj2.  Turquoise: Start codon, ATG; Yellow: His6-tag; 
Grey: BamHI; Red: BamHI; Teal: first codon of the codon-optimised Pfj2 coding sequence, GCA; 
Green; Stop codon, TAA; Pink: KpnI. 
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3.4.4.  Site-directed mutagenesis  
To eliminate the first BamHI site downstream of the His6-tag, pQE30-Pfj2 was subjected to site 
directed mutagenesis.  Site-directed mutagenesis was performed by whole plasmid amplification 
using complementary forward and reverse primers (Refer to Table 2.1, section 2.3.7.1).  The 
primers were designed to amplify the 4988 bp sequence of pQE30-Pfj2.  Following 
amplification, the product was treated with DpnI to remove parental plasmid and analysed by 
0.8% agarose gel electrophoresis.  The results are shown in Figure 3.9.   
Lane 1 contains the parental plasmid, undigested pQE30-Pfj2.  Lane 2 contains the mutagenesis 
amplification product, pQE30-Pfj2, treated with DpnI.  The resolved undigested pQE30-Pfj2 
bands in lane 1 serves as a control to determine whether DpnI is able to cleave the template DNA 
of the mutagenic amplified product in lane 2.  There is no band in the mutated amplified product 
in lane 2 corresponding to the undigested pQE30-Pfj2 band observed in lane 1.  This suggests 
that the DpnI has successfully cleaved the template DNA of the mutagenic amplified product.  
However, if the DNA bands observed in lane 2 corresponds with the undigested pQE30-Pfj2 in 
lane 1, the DpnI would have not been effective in cleaving the template pQE30-Pfj2 of the 
amplified product.  Lanes 3 and 4 represents linearised pQE30-Pfj2 controls restricted with 
BamHI and KpnI respectively resolved at the expected size of 4988 bp to indicate where the 
mutagenic amplification product should resolve. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Site-directed mutagenesis on pQE30-Pfj2.  Lane M: λ PstI molecular marker; Lane 1: 
Undigested pQE30-Pfj2; Lane 2: DpnI treated mutagenesis amplification product, pQE30-Pfj2; Lane 3: 
pQE30-Pfj2 restricted with BamHI; Lane 4: pQE30-Pfj2 restricted with KpnI.   
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3.4.5.  Verification of pQE30-Pfj2 following site-directed mutagenesis 
To confirm that site-directed mutagenesis was successful, DNA sequencing was performed using 
pQE30 forward and reverse primers as described in section 3.3.3.  The results are shown in 
Figure 3.10.  
DNA sequencing showed that the first BamHI site downstream of the His6-tag was successfully 
mutated by deletion mutagenesis, thereby, correcting the frame-shift mutation.  Two nucleotides, 
GG, were deleted from the first BamHI site leaving ATCC highlighted in grey.  The mutagenesis 
eliminated the frame-shift in the coding sequence of His6-Pfj2 and corrected the open reading 
frame.  The second BamHI site highlighted in red is downstream of the His6-tag (yellow).  The 
start codon, ATG, is positioned at the 5’ end of the nucleotide sequence and is highlighted in 
turquoise.  GCA, highlighted in teal, represents the first codon of the codon-optimised Pfj2 
coding sequence.  
5'CCTCGAGAAATCATAAAAAATTTATTTGCTTTGTGAGCGGTCCACAATTATAATAGATTCA
ATTGTGAGCGGATAACAATTTCACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGAG
GATCGCATCACCATCACCATCACATCCGATCCAATGGATCCGCATGCGCACGTGGTATGGAT
TATTACAAACGTCTGGGCGTGAAACGCAATGCGACCAAAGAAGATATTTCTAAAGCCTACC
GCCAGCTGGCAAAAGAATATCATCCGGATATCGCCCCGGATAAAGAAAAAGATTTCATCGA
AATCGCGAACGCCTACGAAACGCTGAGCGATCCGGAAAAACGTAAAATGTACGATATGTAC
GGTGAAGATTATGCGCAGGGCGGTATGGGCGG_ _ _GGTCACGTTACCAGTTATCAGGAAC 
TGACCAAGAAAAAATACGAAAGTGGCCAGTGCCATGAAAAAGATAGCCAGATTTGCTTTTT
CATCCTGAAACTGCTGAAGAAAAACTATAAAAGCTTCGATGAAGATATCAAAAAAGTGGCA
AACAAATTCAGCTCTGATCCGCTGAAAATTCTGTATATTAACATCTACCAGCAGCCGTATAT
CCTGGATTCTTTTGGTCTGAGTAACAATATTCAGTACAGCAATGGCCTGATCCTGGTGGCGTT
CCGTCCGAAACGCCAGAAATTTAAAGTTTATGATGGCGATGTGAACGTTGAAAATGTGCATA
AATTCGTTGATAACGTTGTTAGTGGTGGCATTCCGATCAACCAGAATATTAAACGCAGCCTG
AAATTTGTGCACGTTGAACAGTATGATGATGAACTGTAAGGTACCCCGGGTCGACCTGCAGC
C'3 
Figure 3.10:  Nucleotide sequence of pQE30-Pfj2 following site-directed mutagenesis. Turquoise: 
Start codon, ATG; Yellow: His6-tag; Grey: Mutated site; Red: BamHI; Teal: first codon of the codon-
optimised Pfj2 coding sequence: Green; Stop codon, TAA; Pink: KpnI. 
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3.5.  Expression of His6-Pfj2 and His6-BiP in E. coli M15[pREP4] cells 
3.5.1.  Heterologous expression of His6-Pfj2 
pQE30-Pfj2 was transformed into E. coli M15[pREP4] cells and His6-Pfj2 expression in E. coli 
M15[pREP4] cells induced with 1 mM IPTG at 37⁰C.  Expression was assessed every hour for 5 
hours and at 12 hours post-induction. The proteins were analysed by 12% SDS-PAGE and 
Western immunoblotting.  The results are shown in Figure 3.11. 
A band corresponding to the expected mobility of His6-Pfj2 at approximately 62 kDa can be seen 
in lanes 2-7 in Figure 3.11A.  Apparent on the gel is a protein band that is increasing in intensity 
over time with maximal intensity at 12 hours post-induction (lane 7).  The band is absent in the 
un-induced sample (lane 1).  Lane 8 contains the 41 kDa His6-PFA (plasmid generously donated 
by Mr Michael O. Daniyan) used to approximate the size of His6-Pfj2.  To confirm the presence 
of His6-Pfj2, Western immunoblotting using anti-His6 antibodies was performed (Figure 3.11B).  
Prominent bands representing His6-Pfj2 of increasing intensity were observed (lanes 2-7).  A 
band was detected for His6-PFA (lane 8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Expression of His6-Pfj2 in E. coli M15[pREP4] cells.  (A) Lane M: PageRuler
TM Plus 
Prestained Protein Ladder;  Lane 1: un-induced His6-Pfj2;  Lane 2: His6-Pfj2 harvested 1 hour post-
induction;  Lane 3: His6-Pfj2 harvested 2 hours post-induction;  Lane 4: His6-Pfj2 harvested 3 hours post-
induction;  Lane 5: His6-Pfj2 harvested 4 hours post-induction;  Lane 6: His6-Pfj2 harvested 5 hours post-
induction;  Lane 7: His6-Pfj2 harvested 12 hours post-induction;  Lane 8: total protein of E. coli 
M15[pREP4] cells expressing His6-PFA. (B) Western immunoblotting confirming induced His6-Pfj2 and 
His6-PFA expression using mouse anti-His6 antibodies (1/5000 dilution) and anti-mouse IgG POD-
labeled antibodies (1/6000 dilution).   
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3.5.2.  Heterologous expression of His6-BiP 
His6-BiP expression in E. coli M15[pREP4] cells was induced with 1 mM IPTG at 37⁰C.  The 
expression of His6-BiP was assessed every hour for 5 hours and 12 hours post-induction. The 
proteins were analysed by 12% SDS-PAGE and Western immunoblotting.  The results are shown 
in Figure 3.12. 
A band corresponding to the expected mobility of His6-BiP at approximately 78 kDa is observed 
in lanes 2-7 in Figure 3.12A.  Maximal protein intensity can be seen in the sample induced four 
hours post-induction in lane 5.  No corresponding protein band is observed in the un-induced 
sample in lane 1.  His6-Pfj2 was used to estimate the approximate size of His6-BiP.  The presence 
of His6-BiP and His6-Pfj2 was confirmed by Western immunoblotting using anti-His6 antibodies 
(Figure 3.12B).  Prominent bands representing His6-BiP of decreasing intensity at 5 and 12 hours 
were observed (lanes 6-7).  A band was detected for His6-Pfj2 (lane 8). 
 
 
 
Figure 3.12: Expression of mammalian His6-BiP in E. coli M15[pREP4] cells.  (A) Lane M: 
PageRulerTM Prestained protein ladder;  Lane 1:  Un-induced His6-BiP;  Lane 2: His6-BiP harvested 1 
hour post-induction;  Lane 3: His6-BiP harvested 2 hours post-induction;  Lane 4: His6-BiP harvested 3 
hours post-induction;  Lane 5: His6-BiP harvested 4 hours post-induction;  Lane 6: His6-BiP harvested 5 
hours post-induction;  Lane 7: His6-BiP harvested 12 hours post-induction;  Lane 8: total protein of E. coli 
M15[pREP4] cells expressing His6-Pfj2. (B) Western immunoblotting for verification of  His6-BiP and 
His6-Pfj2 expression using mouse anti-His6 primary antibody (1/5000 dilution) and anti-mouse IgG POD-
labeled secondary antibody (1/6000 dilution). 
 
 
 
 
_____________________________________________________________________Results 
 
Page | 56  
 
3.6.  Solubility studies  
3.6.1.  Solubility studies of His6-Pfj2 in E. coli M15[pREP4] cells at 37⁰C 
In order to determine whether native or denaturing conditions would be used for purification of 
His6-Pfj2, it was necessary to determine its solubility in E. coli M15[pREP4] cells.  Protein 
expression was induced and cells harvested 12 hours post induction and separated into 
supernatant (S) and pellet (P) fractions by centrifugation.  The samples were analysed by 12% 
SDS-PAGE and Western immunoblotting.  The results are shown in Figure 3.13.  
No corresponding protein band was observed in the un-induced sample in lane 1 as expected.  
Distinct protein bands corresponding to the expected mobility of His6-Pfj2 can be seen in the 
total protein (TP) and pellet fraction in lanes 2 and 4 respectively.  No corresponding band was 
evident in lane 3 which contains the supernatant fraction.  His6-PFA in lane 5 is 41 kDa in size 
and was used to estimate the size of His6-Pfj2.  To detect His6-Pfj2 and His6-PFA, Western 
immunoblotting using anti-His6 antibodies was carried out (Figure 3.13B).  Prominent bands 
were observed for His6-Pfj2 in the total protein, pellet fraction and His6-PFA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13:  Solubility analysis of His6-Pfj2 in E. coli M15[pREP4] cells at 37⁰C.  (A)  Lane M: 
PageRulerTM Plus Prestained Protein Ladder;  Lane U: total cell extract from uninduced sample; Lane 1: 
total cell extract from 12 hour un-induced sample; Lane 2: total protein from 12 hour induced sample; 
Lane 3: supernatant fraction from 12 hour induced sample;  Lane 4: pellet fraction from 12 hour induced 
sample;  Lane 5: total cell extract of E. coli M15[pREP4] cells expressing His6-PFA.  (B)  Western 
immunoblotting for verification of the detected His6-Pfj2 and His6-PFA using mouse anti-His6 antibodies 
(1/5000 dilution) and anti-mouse IgG POD-labeled antibodies (1/6000 dilution).   
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3.6.2.  Solubility studies of His6-Pfj2 in E. coli M15[pREP4] cells at 20⁰C 
In an attempt to improve solubility, an induction experiment was performed in E. coli 
M15[pREP4] cells at 20⁰C with 0.4 mM IPTG.  Cells were harvested at A600 of 0.4 and 0.6.  The 
harvested cells were separated into supernatant and pellet fractions and samples analysed by 12% 
SDS-PAGE and Western immunoblotting.  The results are shown in Figure 3.14. 
His6-Pfj2 was not observed in the supernatant fraction (lanes 1 and 2).  Distinct protein bands 
can be seen in the induced pellet fraction at A600 of 0.4 and 0.6 in lanes 3 and 4. The presence of 
His6-Pfj2 was confirmed by Western immunoblotting using anti-His6 antibodies.  Prominent 
bands representing His6-Pfj2 were detected in the pellet fraction at A600 of 0.4 and 0.6, and not in 
supernatant fractions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14:  Solubility analysis of His6-Pfj2 in E. coli M15[pREP4] cells at 20⁰C.  (A) Lane M: 
Precision Plus ProteinTM Dual Color Standards;  Lane 1: supernatant induced at 0.4;  Lane 2: supernatant 
induced at 0.6;  Lane 3: pellet induced at 0.4;  Lane 4: pellet induced at 0.6. (B) His6-Pfj2 detection by 
Western immunoblotting using mouse anti-His6 primary antibody (1/5000 dilution) and ECL anti-mouse 
IgG HRP-conjugated secondary antibody (1/5000 dilution). 
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3.7.  Purification of His6-Pfj2 and His6-BiP 
3.7.1.  Denaturing purification of His6-Pfj2 from E. coli M15[pREP4] cells 
Because His6-Pfj2 was found to be present in the insoluble fraction, native purification was not 
possible.  His6-Pfj2 was purified under denaturing conditions in 8 M urea using Ni-chelating 
affinity column.  Sequential washes and elutions under native conditions were then performed to 
refold His6-Pfj2.  The progress of the purification was analysed by 12% SDS-PAGE.  The results 
are shown in Figure 3.15. 
Several protein bands including His6-Pfj2 were present in the total protein fraction after 
sonication in lane 1.  Wash steps with 50 mM imidazole were carried out, and are represented in 
lanes 2 and 3 in which protein bands were absent.  Following washing, the protein was eluted 
with 1 M imidazole.  Lanes 4-9 contain samples of the eluted protein.  As can be seen from 
Figure 3.15, the majority of the protein corresponding to the expected mobility of His6-Pfj2 was 
eluted in the third elution in lane 6.  Faint protein bands corresponding to the expected mobility 
of His6-Pfj2 are present in elutions 2 and 4 (lanes 5 and 7).  Several bands were also present 
below the expected mobility of His6-Pfj2 in elutions 2-4 (lanes 5-7).  No proteins bands were 
evident in elutions 1, 5 and 6 (lanes 4, 8, and 9).    
 
 
 
 
 
 
 
 
 
 
Figure 3.15:  Urea denaturing purification of His6-Pfj2 from E. coli M15[pREP4] cells using nickel 
affinity chromatography.  Lane M: PageRulerTM Prestained protein ladder; Lane 1: total protein in 8M 
urea; Lane 2: wash step with 50 mM imidazole in 4M urea; Lane 3: wash step with 50 mM imidazole 
without urea;  Lanes 4-9: elutions with 1 M imidazole. 
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Following elution, protein fractions in elutions 2 and 3 which contained purified His6-Pfj2 were 
chosen for dialysis. Purified His6-Pfj2 was dialysed and analysed by 12% SDS-PAGE and 
Western immunoblotting. The results are shown in Figure 3.16.   
Panel A which contains 2.5 μg of loaded protein shows a faint band representing His6-Pfj2. The 
protein was detected by Western immunoblotting using anti-His6 antibodies (Panel B).  The 
purification experiment was performed in triplicate for future ATPase assays yielding 0.714 
mg/L, 0.954 mg/L and 0.816 mg/L of protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16:  Dialysed His6-Pfj2. Panel (A) Lane M:  PageRuler
TM Plus Prestained Protein Ladder;  
Lane 1: His6-Pfj2.  Panel (B) His6-Pfj2 was detected by Western immunoblotting using mouse anti-His6 
antibodies (1/5000) and anti-mouse IgG POD-labeled antibodies (1/6000). 
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3.7.2.  Native purification of His6-BiP from E. coli M15[pREP4] cells 
Batch purification of His6-BiP in E. coli M15[pREP4] cells was carried out under native 
conditions using nickel affinity chromatography.  The progress of the purification was analysed 
by 12% SDS-PAGE and Western immunoblotting.  The results are shown in Figure 3.17. 
Several protein bands including His6-BiP were present in the total protein after sonication in lane 
1.  Protein bands were evident in lane 2, representing the flow through which contain the 
unbound protein.  Wash steps with 40 mM imidazole were carried out, and unbound protein 
fractions are present in lanes 3-5.  Following washing, the protein was eluted with 100 mM 
imidazole.  Lanes 6-8 contain samples of eluted protein.  As can be seen from Figure 3.17, the 
majority of the protein corresponding to the expected mobility of His6-BiP was eluted in the first 
elution in lane 6.  Significant amounts of protein were eluted in lanes 7 and 8.  Lane 9 contains 
the bead fraction in which a prominent protein band is evident.  To confirm the presence of His6-
BiP, Western immunoblotting using anti-His6 antibodies was performed (Figure 3.17B).  
Prominent bands representing His6-BiP were observed (lanes 1-9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17:  Native purification of His6-BiP from E. coli M15[pREP4] cells by nickel affinity 
chromatography.  (A)  SDS-PAGE analysis illustrating Lane M: PageRulerTM Prestained protein ladder;  
Lane 1:  total protein;  Lane 2: unbound protein fraction;  Lanes 3-5:  wash steps with 40 mM imidazole;  
Lanes  6-8:  elutions with 100 mM imidazole;  Lane 9: eluted nickel-charged bead fraction.  (B)  His6-
BiP was detected by Western immunoblotting using mouse anti-His6 antibodies (1/5000) and anti-mouse 
IgG POD-labeled antibodies (1/6000). 
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Following elution the protein was dialysed to remove excess salt and analysed by 12% SDS-
PAGE and Western immunoblotting.  The results are shown in Figure 3.18.   
 
Panel A which contains 3.7 μg of loaded protein shows a prominent band representing His6-BiP.  
However, it is evident from the amount of protein observed on the gels in figures 3.16 and 3.18 
that the calculated amount of 3.7 μg for His6-BiP is underestimated.  The presence of His6-BiP 
was confirmed by Western immunoblotting using anti-His6 antibodies. The purification 
experiment was performed in triplicate for subsequent ATPase assays yielding 7.392 mg/L, 
8.008 mg/L and 10.252 mg/L of protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18:  Dialysed His6-BiP.  (A) Lane M:  PageRuler
TM Plus Prestained Protein Ladder;  Lane 1: 
His6-BiP.  (B) His6-BiP was detected by Western immunoblotting using mouse anti-His6 antibodies 
(1/5000) and anti-mouse IgG POD-labeled antibodies (1/6000). 
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3.8.  ATPase assays of His6-Pfj2 and mammalian His6-BiP 
To investigate whether His6-Pfj2 was capable of stimulating the chaperone activity of 
mammalian His6-BiP, ATPase assays were performed.  The release of inorganic phosphate was 
spectrophotomerically quantified using ammonium molybdate and ascorbic acid at 850 nm.  
Alfalfa Hsp70-1 and human His6-Hsj1a were used as controls.  ATPase activity was expressed as 
nmolPi/min/mg. 
3.8.1.  Phosphate standard curve 
Prior to ATPase assay, a phosphate standard curve was generated to extrapolate the 
concentration of phosphate released (Figure 3.19). The linear regression equation was y = 
0.0544x + 0.0293 and the correlation coefficient was R2 = 0.9994. 
 
 
 Figure 3.19: Phosphate standard curve.  The phosphate concentrations used were 0-60 nmol at 37⁰C.  
The absorbance was read at 850 nm. 
 
 
 
 
 
 
 
 
 
 
y = 0.0544x + 0.0293 
R2 = 0.9994 
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3.8.2.  ATPase activity 
The ATPase activity of His6-BiP was determined alone and in the presence of His6-Pfj2 and 
His6-Hsj1a.  The ATPase activity of alfalfa Hsp70-1 was determined alone as positive control.   
The result of phosphate released over time (Figure 3.20) shows a high rate of phosphate released 
for alfalfa Hsp70-1 (1).  His6-BiP in the presence of His6-Hsj1a (2) shows an increase in the rate 
of phosphate released when compared with His6-BiP alone (4).  However, no increase was 
observed with His6-BiP in the presence of His6-Pfj2 (3).  No intrinsic phosphate release activities 
were observed with His6-Pfj2 (5) and His6-Hsj1a (6). 
 
 
 
 
 
 
 
 
 
 
Figure 3.20:  Phosphate released over time.  1: Alfalfa Hsp70-1(0.05 μM);  2: His6-BiP and His6-Hsj1a 
each with a concentration of 0.4 μM; 3: His6-BiP and His6-Pfj2 each with a concentration of 0.4 μM;  4: 
His6-BiP (0.04 μM);  5: His6-Pfj2 (0.04 μM);  6: His6-Hsj1a (0.04 μM).  The phosphate versus time graph 
was generated through linear regression from the combination of data obtained from three independent 
ATPase assays using freshly purified proteins for each assay.   
Table 3.3:  Phosphate released over time 
Protein Linear regression equation Coefficient of correlation 
Alfalfa Hsp70-1 y = 0.0638x + 0.0401 R2 = 0.9999 
His6-BiP y = 0.0188x + 0.1384 R
2 = 0.9929 
His6-BiP and His6-Pfj2 y = 0.0196x + 0.0664 R
2 = 0.9981 
His6-BiP and His6-Hsj1a y = 0.0262x + 0.2287 R
2 = 0.9871 
His6-Hsj1a y = 0.0001x – 0.0011 R
2 = 0.2392 
His6-Pfj2 y = 0.0003x + 0.0261 R
2 = 0.5001 
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The ability of His6-Pfj2 and His6-Hsj1a to stimulate the ATPase activity of His6-BiP is described 
Figure 3.21.  As indicated with the asterisk (*), a significant stimulation of His6-BiP ATPase 
activity was observed in the presence of His6-Hsj1a when compared with His6-BiP alone, and  no 
stimulation was observed in the presence of His6-Pfj2.  As expected, His6-Pfj2 and His6-Hsj1a 
alone shows no intrinsic ATPase activity.  Alfalfa Hsp70-1 has a high intrinsic ATPase activity 
as expected.  The estimated values of the specific ATPase activity are presented in Table 3.4. 
 
 
Figure 3.21:  ATPase assay.  Alfalfa Hsp70-1 (0.05 μM; value shown on graph is 1/10th of the original 
value); His6-BiP (0.4 μM); His6-BiP and His6-Pfj2 each with a concentration of 0.4 μM; His6-BiP and 
His6-Hsj1a each with a concentration of 0.4 μM; His6-Hsj1a (0.4μM); His6-Pfj2 (0.4μM).  The ATPase 
assay graph was generated from the combination of data obtained from three independent ATPase assays 
using freshly purified proteins for each experiment.  * represents significant stimulation. 
 
Table 3.4:  ATPase activity of proteins 
Protein ATPase activity (nmolPi/min/mg) 
Alfalfa Hsp70-1 364.36 ± 16.67 
His6-BiP 12.07 ± 3.92 
His6-BiP and His6-Pfj2 12.59 ± 4.06 
His6-BiP and His6-Hsj1a 16.77 ± 3.84 * 
His6-Hsj1a _ 
His6-Pfj2  _  
*Student’s T-Test showed significant stimulation (p<0.05) of ATPase activity of mammalian His6-BiP in 
the presence of His6-Hsj1a when compared with His6-BiP alone.  
* 
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4.1.  Overall discussion  
Many cases of human mortalities are reported annually as a result of malaria.  P. falciparum is a 
protozoan parasite that causes a severe form of malaria, and nearly all malaria deaths result from 
infection by this species of parasite (World Health Organisation, 2012).  The P. falciparum 
genome encodes at least 43 Hsp40s including a type II Hsp40, Pfj2. Pfj2 is particularly 
interesting as it is potentially homologous to the human ER Hsp40, ERdj5, which has been 
shown to facilitate protein quality control in the ER by promoting the degradation of misfolded 
proteins (Ushioda et al., 2008).  Pfj2 could potentially perform the same function in P. 
falciparum thereby promoting the parasite’s survival. Biochemical characterisation could provide 
some insights pertaining the function of Pfj2 in vivo and its potential as a drug target, given that 
P. falciparum has developed resistance to many of the available anti-malarial drugs thus 
requiring that new drugs and drug targets be identified.  Therefore, the overall aim of this study 
was to express and purify His6-Pfj2 in a bacterial system, and investigate the ability of the 
protein to stimulate the activity of the mammalian Hsp70, His6-BiP.   
Pfj2 has been identified as a P. falciparum Hsp40 chaperone that may facilitate protein quality 
control in the ER, but has not been well studied or documented in the literature.  ER proteins are 
involved in oxidative protein folding by acting as catalysts and folding assistants. They may also 
act as oxidases or reductases by catalysing disulfide bond formation of newly synthesised 
polypeptides in the ER or as isomerases to correct non-native disulfide bonds and as chaperone 
or co-chaperones to prevent protein aggregation and facilitate folding of nascent proteins.  ER 
proteins consist of members of the Hsp70 family of proteins including BiP.  (Haas and Wabl, 
1983).  Cofactors of BiP belonging to the Hsp40 class of proteins include ERdj1–7 (Otero et al., 
2010).  
Studies have identified several ER J-proteins termed ERdj1/Mtj1 (Brightman et al., 1995; 
Chevalier et al., 2000), ERdj2/hSec63 (Skowronek et al., 1999; Tyedmers et al., 2000), 
ERdj3/HEDJ (Bies et al.,1999; Lau et al., 2001; Yu et al., 2000), ERdj4/Mdj1 (Prols et al., 2001;  
Shen et al., 2002), and ERdj5/JPDI that has both a J-domain and oxidoreductase activity 
(Cunnea et al., 2003, Hosoda et al., 2003), ERdj6/p58IPK(Yan et al., 2002) and ERdj7(Zahedi et 
al., 2009).  ERdj5 was cloned from human (Cunnea et al., 2003) and has an N-terminal J-domain 
followed by four thioredoxin-like sequences with a -CXYC- variant motif -CSHC-,  -CPPC-, -
CHPC- and CGPC-.  In addition, ERdj5 has a C-terminal -KDEL ER retention sequence (Cunnea 
et al., 2003, Hosada et al., 2003).  ERdj5 has been shown to assist protein quality control by 
cleaving disulfide bonds of misfolded proteins in the ER as a result of it reductase activity and 
interacts through its J-domain in an ATP-dependent manner with BiP, an ER-resident member of 
the Hsp70 chaperone family involved in ER-associated degradation and protein translocation 
(Ushioda et al., 2008). 
Interestingly Pfj2 chaperone is potentially homologous to the human ER Hsp40, ERdj5 in terms 
of sequence homology (Botha et al., 2007). The most intriguing feature underlining the similarity 
between ERdj5 and Pfj2 is the presence of J-domain and thioredoxin-like domain on the same 
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polypeptide backbone. These features are essential to catalyse the disulfide bond formation and 
isomerisation in the ER as well as the reduction of disulfide bonds in the ER lumen prior to 
dislocation of proteins destined for degradation (Tortorella et al., 1998, Fagioli et al., 2001). 
Since many membrane and secretory proteins possess disulfide bonds that are essential to 
achieve their native state Pfj2, like ERdj5 and other PDI related proteins in the ER , having these 
unique features may function as a catalyst in the oxidation and isomerisation of disulfides on 
nascent polypeptides undergoing folding in the oxidising environment of the ER (Noiva, 1999). 
These proteins may also be involved in the dislocation of short-lived proteins targeted for 
proteasomal degradation (Tsai et al., 2002). However, an important question to be addressed in 
this study was to determine whether Pfj2 acts as a thioredoxin, a PDI-like protein or as a DnaJ 
partner for a corresponding parasite Hsp70 BiP. 
 
In P. falciparum, several proteins have been annotated as PDI-like or putative PDI in the 
PlasmoDB database (http://www.plasmoDB.org) (Bahl et al., 2003). Among these are  
MAL8P1.17, (PfPDI), PFI0950w, PF14_0694 and PF11_0352 and Pfj2 which possesses a 
putative N-terminal signal-peptide, a putative C-terminal ER-retention sequence, a putative 
PEXEL motif and a putative thioredoxin motif according to a Prosite analysis 
(http://www.expasy.ch/prosite). Notably, Pfj2 has a putative thioredoxin motif, indicating that it 
might possess oxidoreductase activity and therefore could serve as potential target for developing 
a new anti-malarial strategies anchored on impaired folding of exported parasite proteins. The 
analysis of the amino acid sequence of Pfj2 showed the presence of a J-domain with conserved 
HPD motif and G/F region but low sequence similarity and identity when aligned with other type 
II Hsp40s. Botha et al. (2007) observed that Pfj2 appears to be distinctly different from the other 
PEXEL/HT containing type II Hsp40 proteins due to the overlap of the proposed PEXEL/HT 
motif with helix II of the J-domain.  This is contrary to what is seen in other type II Hsp40 
proteins where the PEXEL/HT motifs precede the J-domain. This observation, coupled with the 
presence of thioredoxin motif, may explain the low level of sequence similarity and identity 
between these proteins.  The presence of a J-domain and putative thioredoxin motif in the amino 
acid sequence of Pfj2 and the fact that they are both ER resident proteins may indicate a degree 
of functional relationship between ERdj5 and Pfj2.   
In this study, the ability of His6-Pfj2 to stimulate the ATPase activity of Hsp70 was investigated. 
Multiple alignment of the amino acid sequence of PfBiP, hamster GRP-78/BiP, MsHsp70-1 and 
S. cerevisiae BiP showed that these proteins are highly conserved at the amino acid level.  The 
proteins also exhibited similarities in terms of protein sizes and the number of amino acid 
residues.  The results of this analysis and the availability of hamster GRP-78/BiP accounts for its 
use in this study.   
The codon optimised coding sequence of Pfj2 was synthesised for use in this study. The native 
Pfj2 coding sequence was codon-optimised and cloned into pUC57 cloning vector by GenScript.  
pUC57-Pfj2 was engineered to include BamHI and KpnI restriction sites at the 5’ end and 3’ end 
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of the sequence to facilitate cloning into pQE30.  An initial attempt at expressing the native 
sequence was unsuccessful (data not shown).  The presence of rare codons which are not 
recognised by the E. coli translational machinery accounted for the need for codon optimisation. 
Codon optimisation helps to improve codon usage and therefore maximise protein expression in 
the organism of choice, in this case E. coli (Burgess-Brown et al., 2008). 
The availability of bacterial expression systems, ease of growth and high level of protein 
expression within a short period of time made this the system of choice for the expression and 
purification of His6-Pfj2 (QIAexpress® The Complete System for 6xHis Technology).  
However, bacterial expression systems have inherent disadvantages. These include protein 
aggregation and formation of inclusion body resulting in protein insolubility (Thomas and 
Baneyx, 1996).  These problems can be overcome by reducing IPTG concentration, temperature 
and time of expression (Hannig and Makrides, 1998).  The expression vector, pQE30, has been 
designed for high-level expression of His6-tagged proteins in E. coli based on the T5 promoter 
transcription–translation system (Bujard et al., 1987; Stüber et al., 1990).  E. coli M15[pREP4] 
cells generate high levels of lac repressor protein by pREP4 to ensure tight control at the 
transcriptional level (QIAexpress® The Complete System for 6xHis Technology). 
 
The cloning of pQE30-Pfj2 was initiated by double restriction digest of pUC57-Pfj2 and the 
vector pQE30 with BamHI and KpnI followed by ligation.  Following sequencing analysis an 
additional BamHI site was detected downstream of the His6-tag resulting in a frame-shift 
mutation necessitating the use of site directed mutagenesis.  There are several approaches to 
mutagenesis including site-directed mutagenesis, random mutagenesis and in vitro saturation.  
Site-directed mutagenesis is typically performed using the PCR. Using this technique, nucleotide 
substitutions, additions and deletions can be made in the sequence (Kadowaki et al., 1989). 
Primer extension (Ho et al., 1989), inverse PCR (Ochman et al., 1988) and cassette mutagenesis 
which require synthetic oligonucleotides for amplification can also be performed (Zoller, 1991).  
Random mutagenesis can be introduced by chemical mutagenesis, error prone PCR (enzymatic 
mutagenesis), PCR with degenerate primers, UV irradiation, mutator strains, nucleotide 
analogues, or DNA recombination (Kuchner and Arnold, 1997). However, advances in 
oligonucleotide synthesis, identification and construction of new commercial polymerases have 
made oligonucleotide PCR based mutagenesis a method of choice for this study.  Following site-
directed mutagenesis, pQE30-Pfj2 was confirmed by restriction digest and DNA sequencing. 
 
The expression and solubility studies were done as an initial step towards formulating the best 
approach for the purification of His6-Pfj2. Following IPTG induction at 37
⁰C in E. coli 
M15[pREP4] cells, SDS-PAGE and Western immunoblotting, maximal protein expression was 
observed at 12 hours post-induction. The results also showed that His6-Pfj2 was largely detected 
in the insoluble or pellet fraction.  Solubility of the protein is not only important for ease of 
purification, but also for maintaining the protein in a folded state, which is necessary for 
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biological activity.  However, various attempts at improving the solubility of His6-Pfj2 including 
expression at lower temperature (20⁰C) and lower IPTG concentration (0.4 μM) did not yield 
soluble proteins.  Furthermore, Pfj2 resides in the ER, an organelle which is lacking in the 
prokaryotic E. coli expression system used in this study.  The ER plays an important role in 
protein synthesis and modification.  The ER compartment facilitates the folding of newly 
synthesised polypeptides and plays a role in the assembly of multimeric proteins (Vitale et al., 
1993).  Proteins are retained in the ER until the correct conformation is attained.  Ridder et al. 
(1995) also reported that proteins which form insoluble inclusion bodies in E. coli are often 
soluble when expressed in yeast.  Therefore, another approach to improve His6-Pfj2 solubility 
may involve expression in a eukaryotic system, for example, yeast or mammalian cells. Such 
systems may facilitate the folding of Pfj2 and prevent its aggregation when over-expressed.  
However, these expression systems are often complicated and expensive (Tolia and Joshua-Tor, 
2006).  
A unique feature of the ER resident proteins include a thioredoxin-like domain which may serve 
as a catalyst in the oxidation and isomerisation of disulfides bonds during the Pfj2 folding 
process in the oxidising environment of the ER (Noiva, 1999).  Determination of Pfj2 secondary 
structure will help to provide insight into its folded state and suitability for use in biological 
assays.  Fourier transform infrared spectroscopy (FTIR) constitutes one of the commonly used 
experimental methods for estimating the secondary structure of polypeptides and proteins (Byler 
and Susi, 1986; Kong and Yu, 2007).   The secondary structure is reflected by the amide I and 
amide II bands.  Amide I absorbed around 1620 to 1690 cm-1 due to stretching vibrations of 
carbonyl (C=O) groups while amide II absorbed around 1480 to 1585 cm-1 due to bending 
vibrations of NH groups (Byler and Susi, 1986; Kong and Yu, 2007).  
The insolubility of His6-Pfj2 expressed in a bacterial system prompted the use of column 
purification under denaturing conditions using 8 M urea.  The disadvantage of this approach is 
that protein may not fold into its correct tertiary structure and functional activity could be 
compromised as the native state is not always attained following full denaturing purification 
(Kathir et al., 2005).  The use of strong denaturants and reducing agents for improving the 
solubility of protein aggregates was described by De Bernardez (1998) and Lilie et al. (1998) and 
successful purification under denaturing conditions while maintaining the functional activities of 
the proteins has also been reported (Matambo et al., 2004; Ramya et al., 2006; Samudzi et al., 
2012).  Purification of highly insoluble proteins by pH adjustment with and without a lower 
concentration of denaturant has been reported as an alternative approach to using strong 
denaturant at high concentration (Singh and Panda, 2005). However, the extreme pH used in this 
technique may prevent proper refolding and subsequently affect the biological functions of the 
protein.  
 
Batch purification of His6-BiP was carried out under native conditions as previously reported 
(Alder et al., 2005).  Although His6-BiP was highly soluble and yielded relatively pure protein, 
Western immunoblotting showed the presence of possible degradation or contamination products 
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which may explain the presence of faint bands below the prominent band of His6-BiP in Figure 
3.17.  Furthermore, a high proportion of the protein remained bound to the nickel charged beads.  
Increasing the imidazole concentration may reduce the binding of protein to the beads, causing 
more protein to be eluted, thereby improving the protein yield.  Moreover, the calculated amount 
of 3.7 μg for His6-BiP appears low.  This is possibly due to an error in the method used to 
estimate protein concentration. Protein concentration for His6-BiP was determined using a 
nanodrop spectrophotometer. Another approach towards measuring protein concentration should 
have been performed. One such method includes Bradford Assay which could perhaps have 
provided a more accurate measurement. 
 
Hsp40s interact with Hsp70 partners, including human BiP, to stimulate cycles of ATP 
hydrolysis and thus allowing Hsp70 proteins to bind and release substrates (Liberek et al., 1991, 
Szabo et al., 1994).  Consistent with a previous report by Cheetham et al. (1994), His6-Hsj1a 
significantly stimulates the ATPase activity of mammalian His6-BiP.  ERdj5 have been shown to 
bind BiP and stimulate its ATPase activity in vitro. (Ushioda et al., 2008).  The results of the 
ATPase assays in this study revealed that, despite domain similarity with ERdj5, His6-Pfj2 did 
not stimulate the ATPase activity of mammalian His6-BiP in the system used.  This indicates that 
His6-Pfj2 may not be capable of functioning as a co-chaperone for mammalian His6-BiP.  A P. 
falciparum Hsp70, for example, PfBiP could be used to determine the chaperone ATPase activity 
of His6-Pfj2.  Since correct folding of His6-Pfj2 is important for co-chaperone activity, possible 
misfolding of the protein may explain the lack of ATPase activity observed.  One approach to 
addressing the problem of protein misfolding is the optimisation of the buffer conditions by the 
addition of agents that could promote protein solubility and enhance refolding (Bondos and 
Bicknell, 2002).  These agents include kosmotropes, for example, magnesium sulfate (MgSO4) 
and calcium sulfate (CaSO4) that generally stabilise the native state of proteins by increasing the 
surface tension of the solvent (Cappel and Gilbert, 1988; Timasheff, 1998).  In addition, the three 
independent ATPase assays that were performed with freshly purified proteins were carried out 
using the same protein concentration for each experiment.  Several His6-Pfj2 concentrations 
could be used in further ATPase studies to determine the required protein concentration needed 
to stimulate the ATPase activity of mammalian His6-BiP.  Furthermore, ERdj5 could be included 
as Hsp40 control since it has been shown to possess chaperone activity by stimulating human 
BiP (Ushioda et al., 2008).   
  
4.2.  Conclusions 
The overall aim of this study was to express and purify codon-optimised His6-Pfj2 in a bacterial 
system, and investigate the ability of the protein to stimulate the activity of mammalian His6-BiP 
using ATPase assays.  The codon-optimised coding sequence of Pfj2 was successfully inserted 
into the prokaryotic expression vector, pQE30 to facilitate overproduction of a histidine-tagged 
Pfj2.  His6-Pfj2 and His6-BiP were successfully expressed in E. coli M15[pREP4] cells and 
purified using nickel affinity chromatography under denaturing and native conditions 
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respectively for use in ATPase assays.  ATPase assays were performed and the results showed 
that His6-Pfj2 did not stimulate the chaperone activity of mammalian His6-BiP in this system 
suggesting that it may not act as a co-chaperone.  However, optimisation of the assay is 
necessary to validate this observation.  This study has created a platform for future molecular and 
cellular characterisation of Pfj2. 
 
4.3.  Future work 
Further studies on Pfj2 can be performed.  The solubility and purification of His6-Pfj2 could be 
improved using several approaches.  One such approach could be to express His6-Pfj2 in several 
E. coli strains in order to find a strain of E. coli which produces the greatest amount of His6-Pfj2. 
Following successful optimisation of the purification method, further in vitro characterisation to 
determine the specific interacting partners of Pfj2 could be investigated.  This may include the 
extension of ATPase assays to other Hsp70s of human and P. falciparum origin, malate 
dehydrogenase (MDH) assay and Surface Plasmon Resonance (SPR).  In addition, the ATPase 
assay of His6-Pfj2 interaction with mammalian His6-BiP could be validated by using a range of 
His6-Pfj2 concentrations to determine the optimal protein concentration required to elicit the 
stimulation of the ATPase activity of mammalian His6-BiP.  Furthermore, a P. falciparum BiP 
(PfBiP) and ERdj5 could be included as controls used in future ATPase assays. 
 
In vivo studies of His6-Pfj2 could be performed.  These include reductase assays which could be 
performed to test for the ability of His6-Pfj2 to reduce disulfide bonds, thus promoting unfolding 
of proteins with disulfide bonds.  This would be evidence that His6-Pfj2 is involved with PfBiP 
and the translocon in retrograde transport and degradation of protein in vivo.  The purified His6-
Pfj2 could be used to generate chicken antibodies (IgYs), which can be applied in various cell 
biological assays including immunofluorescence staining and analysis to determine the 
localisation of endogenous Pfj2 in P. falciparum infected erythrocytes using confocal 
microscopy.  Finally, co-localisation studies could be performed to investigate possible 
interactions between Pfj2 and potential PfHsp70 partners using confocal microscopy and 
transmission electron microscopy, and confirmed by co-immunoprecipitation experiments using 
cell lysates expressing His6-Pfj2. 
  
 
 
 
 
 
_____________________________________________________________________References 
 
Page | 72  
 
REFERENCES  
Aikawa,M., 1988. Human Cerebral Malaria. The American Journal of Tropical Medicine and 
Hygiene, 39, 3-10. 
 
Alder,N., Shen,Y., Brodsky,J., Hendershot,L., Johnson,A., 2005. The molecular mechanisms 
underlying BiP-mediated gating of the Sec61 translocon of the endoplasmic reticulum. Journal 
of cell Biology, 168, 389-399. 
 
Ansorge,I., Benting,J., Bhakdi,S., Lingelbach,K., 1996. Protein sorting in Plasmodium 
falciparum-infected red blood cells permeabilized with the pore-forming protein streptolysin O. 
Biochemical Journal, 315, 307-314. 
Bahl,A., Brunk,B., Crabtree,J., Fraunholz,M.J., Gajria,B., Grant,G.R, Ginsburg,H., Gupta,D., 
Kissinger,J.C., Labo,P., Li,L., Mailman,M.D., Milgram,A.J., Pearson,D.S., Roos,D.S., Schug,J., 
Stoeckert,C.J Jr., Whetzel,P., 2003. PlasmoDB: the Plasmodium genome resource. A database 
integrating experimental and computational data. Nucleic Acids Research, 31, 212–215.  
Banumathy,G., Singh,V., Tatu,U., 2002. Host chaperones are recruited in membrane-bound 
complexes by Plasmodium falciparum. Journal of Biological Chemistry, 277, 3902-3912. 
 
Baruch,D.I., Pasloske,B.L., Singh,H.B., Bi,X., Ma,X.C., Feldman,M., Taraschi,T.F., 
Howard,R.J., 1995. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen 
and adherence receptor on the surface of parasitized human erythrocytes. Cell, 82, 77-87. 
Beare,N.A., Taylor,T.E., Harding,S.P., Lewallen,S., Molyneux,ME., 2006. Malarial retinopathy: 
a newly established diagnostic sign in severe malaria. American Journal of Tropical Medicine 
and Hygiene, 75, 790–797. 
Behr,C., Sarthou, J.L., Rogier,C., Trape,J.F., Dat,M.H, Michel,J.C., Aribot,G., Dieye,A.,  
Claverie,J.M., Druihle,P., 1992. Antibodies and reactive T cells against the malaria heat-shock 
protein Pf72/Hsp70-1 and derived peptides in individuals continuously exposed to Plasmodium 
falciparum. The Journal of Immunology, 149, 3321-3330. 
 
Bertolotti,A., Zhang,Y., Hendershot,L.M., Harding,H.P., Ron,D., 2000. Dynamic interaction of 
BiP and ER stress transducers in the unfolded-protein response. Nature Cell Biology, 2, 326-332. 
Bhattacharjee,S., van Ooij,C., Balu,B., Adams,J.H., and Haldar,K., 2008. Maurer’s clefts of 
Plasmodium falciparum are secretory organelles that concentrate virulence protein reporters for 
delivery to the host erythrocyte. Blood, 111, 2418–2426. 
_____________________________________________________________________References 
 
Page | 73  
 
Bies,C., Blum,R., Dudek,J., Nastainczyk,W., Oberhauser,S., Jung,M., Zimmermann,R., 2004. 
Characterization of pancreatic ERdj3p, a homolog of yeast DnaJ-like protein Scj1p. Biological 
Chemistry, 385, 389-395. 
 
Bies,C., Guth,S., Janoschek,K., Nastainczyk,W., Volkmer,J., Zimmermann,R., 1999. A Scj1p 
homolog and folding catalysts present in dog pancreas microsomes. Biological Chemistry, 380, 
1175-1182. 
 
Biswas,S., Sharma,Y.D., 1994. Enhanced expression of P. falciparum heat shock protein 
Pfhsp70-1 at higher temperatures and parasites survival. FEMS Microbiology Letters, 124, 425-
429. 
Bondos,S.E., 2003. Bicknell A. Detection and prevention of protein aggregation before, during, 
and after purification. Analytical Biochemistry, 316, 223–231. 
 
Borges,J.C., Fischer,H., Craievich,A.F., Ramos,C.H.I., 2005. Low Resolution Structural Study of 
Two Human HSP40 Chaperones in Solution. Journal of Biological Chemistry, 280, 13671-
13681. 
 
Borges,J.C., Ramos,C.H.I., 2005. Protein folding assisted by chaperones. Protein and peptide 
letters, 12, 257–261. 
Botha,M., Pesce,E.R., Blatch,G.L., 2007. The Hsp40 proteins of Plasmodium falciparum and 
other apicomplexa: Regulating chaperone power in the parasite and the host. Cell Biology, 39, 
1781-1803. 
Botha,M., Chiang, A.N., Needham,P.G., Stephens,L.L., Hoppe,H.C., 2011. Plasmodium 
falciparum encodes a single cytosolic type I Hsp40 that functionally interacts with Hsp70 and is 
upregulated by heat shock.  Cell Stress Chaperones, 16, 389-401. 
Brightman,S.E., Blatch,G.L., Zetter,B.R., 1995. Isolation of a mouse DNA encoding MTJ1, a 
new murine member of the DnaJ family of proteins. Gene, 153, 249-254. 
 
Brodsky,J.L., McCracken,A.A., 1999. ER protein quality control and proteasome-mediated 
protein degradation. Seminars in Cell & Developmental Biology, 10, 507-513. 
_____________________________________________________________________References 
 
Page | 74  
 
Bujard,H., Gentz,R., Lanzer,M., Stueber,D., Mueller,M., Ibrahimi,I., Haeuptle,M.T., 
Dobberstein,B., 1987. A T5 promoter-based transcription-translation system for the analysis of 
proteins in vitro and in vivo. Methods in Enzymology, 155, 416–433. 
 
Burgess-Brown,N.A., Sharma,S., Sobott,F., Loenarz,C., Oppermann,U., Gileadi,O., 2008.  
Codon optimization can improve expression of human genes in Escherichia coli: A multi-gene 
study. Protein Expression and Purification, 59, 94-102. 
 
Byler,D.M., Susi,H., 1986. Examination of the secondary structure of proteins by deconvolved 
FTIR spectra. Biopolymers, 25, 469–487. 
 
Cappel,R.E., Gilbert,H.F., 1993. Oxidative inactivation of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase and subunit cross-linking involve different dithiol/disulfide centers. 
Journal of Biological Chemistry, 268, 342-348. 
 
Celli A., 1933.  A history of malaria in the Italian campagna from ancient times. London.  
 
 
Chang,H.H., Falick,A.M., Carlton,P.M., Sedat,J.W., DeRisi,J.L., Marletta,M.A., 2008. N-
terminal processing of proteins exported by malaria parasites. Molecular and Biochemical 
Parasitology, 160, 107-115. 
Cheetham,M.E., Caplan,A.J., 1998. Structure, function and evolution of DnaJ: conservation and 
adaptation of chaperone function. Cell Stress & Chaperones, 3, 28-36. 
Cheetham,M., Jackson,A., 1994. Regulation of 70-kDa Heat-Shock-Protein ATPase Activity and 
Substrate Binding by Human DnaJ-Like Proteins, HSJ1a and HSJ1b. European Journal of 
Biochemistry.226, 99-107. 
Chevalier,M., Rhee,H., Elguindi,E.C., Blond,S.Y., 2000.  Interaction of murine BiP/GRP78 with 
the DnaJ homologue MTJ1. Journal of Biological Chemistry, 275, 19620-19627. 
Coppel,R.L., Lustigman,S., Murray,L., Anders,R.F., 1988. MESA is a Plasmodium falciparum 
phosphoprotein associated with the erythrocyte membrane skeleton.  Molecular and Biochemical 
Parasitology, 31, 223-231. 
Cox,F., 2010. History of the discovery of the malaria parasites and their vectors. Parasites & 
Vectors, 3, 5. 
_____________________________________________________________________References 
 
Page | 75  
 
Craig,A., Scherf,A., 2001. Molecules on the surface of the Plasmodium falciparum infected 
erythrocyte and their role in malaria pathogenesis and immune evasion. Molecular and 
Biochemical Parasitology, 115, 129-143. 
Cunnea,P.M., Miranda-Vizuete,A., Bertoli,G., Simmen,T., Damdimopoulos,A.E., Hermann,S., 
Leinonen,S., Huikko,M.P., Gustafsson,J., Sitia,R., Spyrou,G., 2003. ERdj5, an Endoplasmic 
Reticulum (ER)-resident Protein Containing DnaJ and Thioredoxin Domains, Is Expressed in 
Secretory Cells or following ER Stress. Journal of Biological Chemistry, 278, 1059-1066. 
Da Silva,E., Foley,M., Dluzewski,A.R., Murray,L.J., Anders,R.F., Tilley,L., 1994. The 
Plasmodium falciparum protein RESA interacts with the erythrocyte cytoskeleton and modifies 
erythrocyte thermal stability. Molecular and Biochemical Parasitology, 66, 59-69. 
De Bernardez Clark,E., 1998. Refolding of recombinant proteins. Current Opinion in 
Biotechnology, 9, 157-163. 
Demand,J., Lüders,J., Höhfeld,J., 1998.  The Carboxy-Terminal Domain of Hsc70 Provides 
Binding Sites for a Distinct Set of Chaperone Cofactors. Molecular Cell Biology 18, 2023–2028. 
 
Desai,M., ter Kuile,F.O., Nosten,F., McGready,R., Asamoa,K., Brabin,B., Newman,R.D., 2007. 
Epidemiology and burden of malaria in pregnancy. Lancet Infectious Diseases, 7, 93-104. 
 
Dudek,J., Greiner,M., Muller,A., Hendershot,LM., Kopsch,K., Nastainczyk,W., 
Zimmermann,R., 2005. ERj1p has a basic role in protein biogenesis at the endoplasmic 
reticulum. Nature Structural & Molecular Biology, 12, 1008-1014. 
Edman,J.C., Ellis,L., Blacher,R.W., Roth,R.A., Rutter,W.J., 1985. Sequence of protein 
disulphide isomerase and implications of its relationship to thioredoxin. Nature, 317, 267-270. 
Ellgaard,L., Ruddock,L.W., 2005. The human protein disulphide isomerase family: substrate 
interactions and functional properties. EMBO Reports, 6, 28-32. 
Ellgaard,L., Helenius,A., 2001. ER quality control: towards an understanding at the molecular 
level. Current Opinion in Cell Biology, 13, 431-437. 
Ellgaard,L., Molinari,M., Helenius,A., 1999. Setting the Standards: Quality Control in the 
Secretory Pathway. Science, 286, 1882-1888. 
_____________________________________________________________________References 
 
Page | 76  
 
Fagioli,C., Mezghrani,A., Sitia,R., 2001. Reduction of interchain disulfide bonds precedes the 
dislocation of Ig-μ chains from the endoplasmic reticulum to the cytosol for proteasomal 
degradation. Journal of Biological Chemistry, 276, 40962-40967. 
Feldman,D.E., Frydman,J., 2000. Protein folding in vivo: the importance of molecular 
chaperones. Current Opinion in Structural Biology, 10, 26-33. 
Fink,A.L., 1999. Chaperone-Mediated Protein Folding. Physiological Reviews, 79, 425-449. 
Flaherty,K.M., DeLuca-Flaherty,C., McKay,D.B., 1990. Three-dimensional structure of the 
ATPase fragment of a 70K heat-shock cognate protein. Nature, 346, 623-628. 
Foley,M., Tilley,L., Sawyer,W.H., Anders,R.F., 1991. The ring-infected erythrocyte surface 
antigen of Plasmodium falciparum associates with spectrin in the erythrocyte membrane. 
Molecular and Biochemical Parasitology, 46, 137-147. 
Gamo,F.J., Sanz,L.M., Vidal,J., de Cozar,C., Alvarez,E., Lavandera,J.L., Vanderwall,D.E., 
Green,D.V.S., Kumar,V., Hasan,S., Brown,J.R., Peishoff,C.E., Cardon,L.R., Garcia-Bustos,J.F., 
2010. Thousands of chemical starting points for antimalarial lead identification. Nature, 465, 
305-310. 
Genevaux,P., Schwager,F., Georgopoulos,C., Kelley,W.L., 2002. Scanning Mutagenesis 
Identifies Amino Acid Residues Essential for the in Vivo Activity of the Escherichia coli DnaJ 
(Hsp40) J-Domain. Genetics, 162, 1045-1053. 
Greene,M.K., Maskos,K., Landry,S.J., 1998. Role of the J-domain in the cooperation of Hsp40 
with Hsp70. Proceedings of the National Academy of Sciences, 95, 6108-6113. 
Guerin,P.J., Olliaro,P., Nosten,F., Druilhe,P., Laxminarayan,R., Binka,F., Kilama,W.L., Ford,N., 
White,N.J., 2002. The Lancet Infectious Disease, 2, 564-573. 
Haas,I.G., Wabl,M., 1983. Immunoglobulin heavy chain binding protein. Nature, 306, 387-389. 
Hall,T.A., 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis 
program for Windows 95/98/NT. Nucleic Acids Symposium Series, 41, 95–98.  
Hamman,B.D., Hendershot,L.M., Johnson,A.E., 1998. BiP Maintains the Permeability Barrier of 
the ER Membrane by Sealing the Lumenal End of the Translocon Pore before and Early in 
Translocation. Cell, 92, 747-758. 
_____________________________________________________________________References 
 
Page | 77  
 
Han,W., Christen,P., 2003. Mechanism of the Targeting Action of DnaJ in the DnaK Molecular 
Chaperone System. Journal of Biological Chemistry, 278, 19038-19043. 
Hannig,G., Makrides,S.C., 1998. Strategies for optimizing heterologous protein expression in 
Escherichia coli. Trends in Biotechnology, 16, 54-60. 
 
Hennessy,F., Nicoll,W.S., Zimmermann,R., Cheetham,M.E., Blatch,G.L., 2005. Not all J 
domains are created equal: Implications for the specificity of Hsp40-Hsp70 interactions. Protein 
Science, 14, 1697-1709. 
Hiller,N.L., Bhattacharjee,S., van Ooij,C., Liolios,K., Harrison,T., Lopez-Estraño,C., Haldar,K., 
2004. A Host-Targeting Signal in Virulence Proteins Reveals a Secretome in Malarial Infection. 
Science, 306, 1934-1937. 
Ho,S.N., Hunt,H.D., Horton,R.M., Pullen,J.K., Pease,L.R., 1989. Site-directed mutagenesis by 
overlap extension using the polymerase chain reaction. Gene, 77, 51-59. 
 
Hoseki,J., Ushioda,R., Nagata,K., 2010. Mechanism and components of endoplasmic reticulum-
associated degradation. Journal of Biochemistry, 147, 19-25. 
Hosoda,A., Kimata,Y., Tsuru,A., Kohno,K., 2003. JPDI, a Novel Endoplasmic Reticulum-
resident Protein Containing Both a BiP-interacting J-domain and Thioredoxin-like Motifs. 
Journal of Biological Chemistry, 278, 2669-2676. 
http://www.ebi.ac.uk 
(Access 1 December 2011) 
http://www.expasy.ch/prosite 
(Access 1 December 20011) 
http://www.ncbi.nlm.nih.gov 
(Access 1 December 2011) 
Jacquerioz,FA., Croft,AM., 2009. Drugs for preventing malaria in travellers. Cochrane Database 
of Systematic Reviews, 4, CD006491. 
Joiner,K.A., 1991. Rhoptry lipids and parasitophorous vacuole formation: A slippery issue. 
Parasitology Today, 7, 226-227. 
_____________________________________________________________________References 
 
Page | 78  
 
Joshi,B., Biswas,S., Sharma,Y.D., 1992. Effects of heat-shock on P. falciparum viability, growth 
and expression of the heat-shock PfHsp70-1 gene. FEBS Letters, 312, 91-94. 
Kadowaki,H., Kadowaki,T., Wondisford,F.E., Taylor,S.I., 1989.  Use of the polymerase chain 
reaction catalyzed by Taq DNA polymerase for site-specific mutagenesis. Gene, 76, 161-166. 
 
Käll,L., Krogh,A., Sonnhammer,E.L.L., 2005. An HMM posterior decoder for sequence feature 
prediction that includes homology information. Bioinformatics, 21, 251–257. 
 
Kappes,B., Suetterlin,B.W., Hofer-Warbinek,R., Humar,R., Franklin,R.M., 1993. Two major 
phosphoproteins of Plasmodium falciparum are heat shock proteins. Molecular & Biochemical 
Parasitology, 59, 83-94. 
 
Kathir,K.M., Kumar,T.K.S., Rajalingam,D., Yu,C., 2005. Time-dependent changes in the 
denatured state(s) influence the folding mechanism of an all β-sheet protein. Journal of 
Biological Chemistry, 280, 29682-29688. 
 
 
Kelly,W.L., 1998. The J-domain family and the recruitment of chaperone power. Trends in 
Biological Sciences, 23, 222-227. 
Kilejian,A., Jensen,J.B., 1977. A histidine-rich protein from Plasmodium falciparum and its 
interaction with membranes. Bull World Health Organ, 55, 191-197. 
Kong,J., Yu,S., 2007. Fourier Transform Infrared Spectroscopic Analysis of Protein Secondary 
Structures. Acta Biochimica et Biophysica Sinica, 39, 549–559. 
Kooij,T.W.A., Janse,C.J., Waters,A.P., 2006. Plasmodium post-genomics: better the bug you 
know? Nature Reviews Microbiology, 4, 344-357. 
Kuchner,O., Arnold,F.H., 1997. Directed evolution of enzyme catalysts. Trends in 
Biotechnology, 15, 523–530. 
 
Külzer,S., Rug,M., Brinkmann,K., Cannon,P., Cowman, A., Lingelbach,K., Blatch,G.L., 
Maier,A.G., Przyborski,J.M.,  2010. Parasite-encoded Hsp40 proteins define novel mobile 
structures in the cytosol of the P. falciparum-infected erythrocyte. Cellular Microbiology, 12, 
1398–1420. 
_____________________________________________________________________References 
 
Page | 79  
 
Kumar,A., Tanveer,A., Biswas,S, Ram,E.V., Gupta,A., Kumar,B., Habib,S., 2010.  Nuclear-
encoded DnaJ homologue of Plasmodium falciparum interacts with replication ori of the 
apicoplast genome. Molecular Microbiology, 75, 942-956. 
 
Kumar,N., Zhao,Y., Graves,P., Perez Folgar,J., Maloy,L., Zheng,H., 1990. Human immune 
response directed against Plasmodium falciparum heat shock-related proteins. Infection and 
Immunity, 58, 1408–1414. 
 
Kumar,N., Zheng,H., 1992. Nucleotide sequence of a Plasmodium falciparum stress protein with 
similarity to mammalian 78 kDa glucose-regulated protein. Molecular & Biochemical 
Parasitology, 56, 353-356. 
Kumar,N., Koski,G., Harada,M., Aikawa,M., Zheng,H., 1991. Induction and localization of 
Plasmodium falciparum stress proteins related to the heat shock protein 70 family. Molecular & 
Biochemical Parasitology, 48, 47-58. 
Kurisu,J., Honma,A., Miyajima,H., Kondo,S., Okumura,M., Imaizumi,K., 2003. MDG1/ERdj4, 
an ER-resident DnaJ family member, suppresses cell death induced by ER stress. Genes Cells, 8, 
189-202. 
LaCount,D.J., Vignali,M., Chettier,R., Phansalkar,A., Bell,R., Hesselberth,J.R.,   
Schoenfeld,L.W., Ota,I., Sahasrabudhe,S., Kurschner,C., Fields,S., Hughes,R.E., 2005. A protein 
interaction network of the malaria parasite Plasmodium falciparum. Nature, 438, 103-107. 
 
Lau,P.P., Villanueva,H., Kobayashi,K., Nakamuta,M., Chang,B. H., Chan,L., 2001. A DnaJ 
protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing. Journal of 
Biological Chemistry, 276, 46445-46452. 
 
Laufen,T., Mayer,M.P., Beisel,C., Klostermeier,D., Mogk,A., Reinstein,J., Bukau,B., 1999. 
Mechanism of regulation of Hsp70 chaperones by DnaJ cochaperones. Proceedings of the 
National Academy of Sciences, 96, 5452-5457. 
Laveran, A., 1881. Un nouveau parasite trouvé dans le sang de malades atteints de fièvre 
palustre. Origine parasitaire des accidents de l'impaludisme. Bulletins et Mémoires de la Société 
Médicale des Hôpitaux de Paris, 17,158-164.  
 
Li,J., Qian,X., Sha,B., 2009. Heat shock protein 40: structural studies and their functional 
implications. Protein and Peptide Letters, 16, 606-612. 
_____________________________________________________________________References 
 
Page | 80  
 
Liberek,K., Skowyra,D., Zylicz,M., Johnson,C., Georgopoulos,C., 1991. The Escherichia coli 
DnaK chaperone, the 70-kDa heat shock protein eukaryotic equivalent, changes conformation 
upon ATP hydrolysis, thus triggering its dissociation from a bound target protein. Journal of 
Biological Chemistry, 266, 14491-14496. 
Lievremont,J.P., Rizzuto,R., Hendershot,L., Meldolesi,J., 1997. BiP, a Major Chaperone Protein 
of the Endoplasmic Reticulum Lumen, Plays a Direct and Important Role in the Storage of the 
Rapidly Exchanging Pool of Ca2+. Journal of Biological Chemistry, 272, 30873-30879. 
Lilie,H., Schwarz,E., Rudolph, R., 1998. Advances in refolding of proteins produced in E. 
coli. Current Opinion in Biotechnology, 9, 497-501. 
 
Malhotra,J.D., Kaufman,R.J., 2007. The endoplasmic reticulum and the unfolded protein 
response. Seminars in Cell & Developmental Biology, 18, 716-731. 
Marti,M., Good,R.T., Rug,M., Knuepfer,E., Cowman,A.F., 2004. Targeting Malaria Virulence 
and Remodeling Proteins to the Host Erythrocyte. Science, 306, 1930-1933. 
Martinez-Yamout,M., Legge,G.B., Zhang,O., Wright,P.E., Dyson,H.J., 2000. Solution Structure 
of the Cysteine-rich Domain of the Escherichia coli Chaperone Protein DnaJ. Journal of 
Molecular Biology, 300, 805-818. 
Matambo,T.S., Odunuga,O.O., Boshoff,A., Blatch,G.L., 2004. Overproduction, purification, and 
characterization of the Plasmodium falciparum heat shock protein 70. Protein Expression and 
Purification, 33, 214-222. 
 
Mayer,M., Bukau,B., 2005. Hsp70 chaperones: Cellular functions and molecular mechanism. 
Cellular and Molecular Life Sciences, 62, 670-684. 
Meyer,HA., Grau,H., Kraft,R., Kostka,S., Prehn,S., Kalies,K.U., Hartmann,E., 2000. 
Mammalian Sec61 is associated with Sec62 and Sec63. Journal of Biological Chemistry, 275, 
14550-14557. 
Minami,Y., Hohfeld,J., Ohtsuka,K., Hartl,F.U., 1996. Regulation of the heat-shock protein 70 
reaction cycle by the mammalian DnaJ homolog, Hsp40. Journal of Biological Chemistry, 271, 
19617-19624. 
Misra,G., Ramachandran,R., 2009. Hsp70-1 from Plasmodium falciparum: protein stability, 
domain analysis and chaperone activity. Biophysical Chemistry, 142, 55-64.  
_____________________________________________________________________References 
 
Page | 81  
 
Modisakeng,K.W., Jiwaji,M., Pesce,E.R., Robert,J., Amemiya,C.T., Dorrington,R.A., 
Blatch,G.L., 2009. Isolation of a Latimeria menadoensis heat shock protein 70 (Lmhsp70) that 
has all the features of an inducible gene and encodes a functional molecular chaperone.  
Molecular Genetics and Genomics, 282, 185-196. 
 
Newton,P., Proux,S., Green,M., Smithuis,F., Rozendaal,J., Prakongpan,S., Chotivanich,K., 
Mayxay,M., Looareesuwan,S., Farrar,J., Nosten,F., White,N.J., 2001. Fake artesunate in 
southeast Asia. Lancet, 357, 1948-1950. 
Nicoll,W.S., Botha,M., McNamara,C., Schlange,M., Pesce,E.R., Boshoff, A., Ludewig,M.H., 
Zimmermann,R., Cheetham,M.E., Chapple,J.P., Blatch, G.L., 2007. Cytosolic and ER J-domains 
of mammalian and parasitic origin can functionally interact with DnaK. International Journal of 
Biochemistry and Cell Biology, 39, 1357-2725. 
 
Noiva,R., 1999. Protein disulfide isomerase: the multifunctional redox chaperone of the 
endoplasmic reticulum. Seminars in Cell & Developmental Biology, 10, 481–493. 
 
Nyalwidhe,J., Lingelbach, K., 2006. Proteases and chaperones are the most abundant proteins in 
the parasitophorous vacuole of Plasmodium falciparum-infected erythrocytes. Proteomics, 6, 
1563–1573. 
 
Ochman,H., Gerber,A.S., Hartl,D.L., 1988. Genetic applications of an inverse Polymerase Chain 
Reaction. Genetics, 120, 321-623. 
 
Otero,J.H., Lizák,B., Hendershot,L.M., 2010. Life and death of a BiP substrate. Seminars in Cell 
& Developmental Biology, 21, 472-478. 
Pellecchia,M., Szyperski,T., Wall,D., Georgopoulos,C., Wüthrich,K., 1996. NMR Structure of 
the J-domain and the Gly/Phe-rich Region of the Escherichia coli DnaJ Chaperone. Journal of 
Molecular Biology, 260, 236-250. 
Pesce,E.R., Acharya,P., Tatu,U., Nicoll,W.S., Shonhai,A., Hoppe,H.C, Blatch,G.L., 2008. The 
Plasmodium falciparum heat shock protein 40, Pfj4, associates with heat shock protein 70 and 
shows similar heat induction and localisation patterns. International Journal of Biochemistry & 
Cell Biology, 40, 2914-2926. 
_____________________________________________________________________References 
 
Page | 82  
 
Peterson,M.G., Crewther,P.E., Thompson,J.K., Corcoran,L.M., Coppel,R.L., Brown,G.V., 
Anders,R.F., Kemp,D.J., 1988. A second antigenic heat shock protein of Plasmodium 
falciparum, DNA, 7, 71-78. 
 
Plemper,R.K., Bordallo,J., Deak,P.M., Taxis,C., Hitt,R., Wolf,D.H., 1999. Genetic interactions 
of Hrd3p and Der3p/Hrd1p with Sec61p suggest a retro-translocation complex mediating protein 
transport for ER degradation. Journal of Cell Science, 112, 4123-4134. 
Pologe,L.G., Pavlovec,A., Shio,H., Ravetch,J., 1987. Primary structure and subcellular 
localization of the knob-ssociated histidine-rich protein of Plasmodium falciparum. Proceedings 
of the National Academy of Sciences, 84, 7139-7143. 
Price,R., van Vugt,M., Phaipun,L., Luxemburger,C., Simpson,J., McGready,R., ter Kuile,F., 
Kham,A., Chongsuphajaisiddhi,T., White,N.J., Nosten,F., 1999. Adverse effects in patients with 
acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical 
Medicine and Hygiene, 60, 547-555. 
Prols,F., Mayer,M.P., Renner,O., Czarnecki,P.G., Ast,M., Gassler,C., Wilting,J., Kurz,H., Christ,B., 
2001. Upregulation of the cochaperone Mdg1 in endothelial cells is induced by stress and during 
in vitro angiogenesis. Experimental Cell Research, 269, 42-53. 
 
Ramya,T.C.N., Karmodiya,K., Surolia,A., Surolia,N., 2007. 15-Deoxyspergualin Primarily 
Targets the Trafficking of Apicoplast Proteins in Plasmodium falciparum. Journal of Biological 
Chemistry, 282, 6388-6397.  
 
Ramya,T.N.C., Surolia,N., Surolia,A., 2007. 15-Deoxyspergualin inhibits eukaryotic protein 
synthesis through eIF2α phosphorylation. Biochemical Journal, 401, 411–420. 
 
Ramya,T.N.C., Surolia,N.N., Surolia,A., 2006. 15-Deoxyspergualin modulates Plasmodium 
falciparum heat shock protein function. Biochemical and Biophysical Research 
Communications, 348, 585-592. 
 
Reiter,P., 2000. From Shakespeare to Defoe: Malaria in England in the Little Ice Age. Emerging 
Infectious Disease, 6, 1–11. 
 
Ridder,R., Schmitz,R., Legay,F., Gram,H., 1995. Generation of rabbit monoclonal antibody 
fragments from a combinatorial phage display library and their production in the yeast Pichia 
pastoris. Biotechnology, 13, 255-260. 
_____________________________________________________________________References 
 
Page | 83  
 
Robbins,J., Dilworth,S.M., Laskey,R.A., Dingwall,C., 1991. Two interdependent basic domains 
in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear 
targeting sequence. Cell, 64, 615-623. 
 
Rosenthal,P.J., 2008. Artesunate for the Treatment of Severe Falciparum Malaria. New England 
Journal of Medicine, 358, 1829-1836. 
Ross R., 1898. The role of the mosquito in the evolution of the malaria parasite. Lancet, 2, 489. 
Rozendaal,J., 2001. Fake antimalaria drugs in Cambodia. Lancet, 357, 890. 
Rug,M., Maier,A., 2011. The Heat Shock Protein 40 Family of the Malaria Parasite Plasmodium 
falciparum. Life, 63, 1081-1086. 
Sabeti,P., 2008. Natural Selection: Uncovering Mechanisms of Evolutionary Adaptation to 
Infectious Disease. Nature education, 1, 1.  
 
Samudzi,R.R., Leman,P.A., Paweska,J.T., Swanepoel,R., Burt,F.J., 2012. Bacterial expression of 
Crimean-Congo hemorrhagic fever virus nucleoprotein and its evaluation as a diagnostic reagent 
in an indirect ELISA. Journal of Virological Methods, 179, 70-76. 
 
Sargeant,T., Marti,M., Caler,E., Carlton,J., Simpson,K., Speed,T., Cowman,A., 2006. Lineage-
specific expansion of proteins exported to erythrocytes in malaria parasites. Genome Biology, 7, 
R12.1-R12.22. 
Schwaller,M., Wilkinson,B., Gilbert,H.F., 2003. Reduction-Reoxidation Cycles Contribute to 
Catalysis of disulfide Isomerization by Protein-disulfide Isomerase. Journal of Biological 
Chemistry, 278, 7154-7159. 
Sevier,C.S., Kaiser,C.A., 2002. Formation and transfer of disulphide bonds in living cells. 
Nature Reviews Molecular Cell Biology, 3, 836-847. 
Sharma,YD., 1992. Structure and possible function of heat-shock proteins in falciparum malaria. 
Comparative Biochemistry and Physiology, 102, 437-444. 
Shen,J., Chen,X., Hendershot,L., Prywes,R., 2002. ER Stress Regulation of ATF6 Localization 
by Dissociation of BiP/GRP78 Binding and Unmasking of Golgi Localization Signals. 
Developmental Cell, 3, 99-111. 
_____________________________________________________________________References 
 
Page | 84  
 
Shen,Y., Meunier,L., Hendershot,L.M., 2002. Identification  and characterization of a novel 
endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro 
and is induced by ER stress. Journal of Biological Chemistry, 277, 15947-15956. 
Shen,Y., Hendershot,L.M., 2005. ERdj3, a Stress-inducible Endoplasmic Reticulum DnaJ 
Homologue, Serves as a CoFactor for BiP's Interactions with Unfolded Substrates. Molecular 
Biology of the Cell, 16, 40-50. 
Shen,Y., Meunier,L., Hendershot,L.M. 2002. Identification and characterization of a novel 
endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro 
and is induced by ER stress. Journal of Biological Chemistry, 277, 15947-15956. 
 
Shonhai,A., Botha,M., de Beer,T.A., Boshoff,A., Blatch,G.L., 2008. Structure-function study of 
a Plasmodium falciparum Hsp70 using three dimensional modelling and in vitro analyses. 
Protein & Peptide Letters, 15, 1117-1125. 
 
Shonhai,A., Boshoff,A., Blatch,G.L., 2007. The structural and functional diversity of Hsp70 
proteins from Plasmodium falciparum. Protein Science, 16, 1803–1818. 
 
Shonhai,A., Boshoff,A., Blatch,G.L., 2005.  Plasmodium falciparum heat shock protein 70 is 
able to suppress the thermosensitivity of an Escherichia coli DnaK mutant strain. Molecular 
Genetics and Genomics, 4, 70-78.  
 
Singh,S.M., Panda,A.K., 2005. Solubilization and refolding of bacterial inclusion body proteins. 
Journal of Bioscience and Bioengineering, 99, 303-310. 
 
Silva,MD., Cooke,B.M., Guillotte,M., Buckingham,D.W., Sauzet,J.P., et al., 2005. A role for the 
Plasmodium falciparum RESA protein in resistance against heat shock demonstrated using gene 
disruption. Molecular Microbiology, 56, 990-1003.   
Sitia,R., Braakman,I., 2003. Quality control in the endoplasmic reticulum protein factory. 
Nature, 426, 891-894. 
Skowronek,M.H., Rotter,M., Haas,I.G., 1999.  Molecular characterization of a novel mammalian 
DnaJ-like Sec63p homolog. Biological Chemistry, 380, 1133–1138. 
  
_____________________________________________________________________References 
 
Page | 85  
 
Šlapeta,J., Keithly,J.S., 2004. Cryptosporidium parvum mitochondrial-type Hsp70 targets 
homologous and heterologous mitochondria. Eukaryotic Cell, 3, 483-494. 
Sommer,T., Wolf,D.H., 1997. Endoplasmic reticulum degradation: reverse protein flow of no 
return. The FASEB Journal, 11, 1227-1233. 
Stüber,D., Matile,H., Garotta,G., 1990. System for high-level production in Escherichia coli and 
rapid purification of recombinant proteins: application to epitope mapping, preparation of 
antibodies and structure–function analysis. Immunological Methods, 4, 121–152. 
 
Suh,W.C., Lu,C.Z., Gross,C.A., 1999. Structural Features Required for the Interaction of the 
Hsp70 Molecular Chaperone DnaK with Its Cochaperone DnaJ. Journal of Biological Chemistry, 
274, 30534-30539. 
Surolia,N., Padmanaban,G., 1991. Chloroquine inhibits heme-dependent protein synthesis in 
Plasmodium falciparum. Proceedings of the National Academy of Sciences, 88, 4786–4790. 
 
Szabo,A., Langer,T., Schröder,H., Flanagan,J., Bukau,B., Hartl,F.U., 1994. The ATP hydrolysis-
dependent reaction cycle of the Escherichia coli Hsp70 system DnaK, DnaJ, and GrpE. 
Proceedings of the National Academy of Sciences, 91, 10345-10349. 
Thomas,J.G., Baneyx,F., 1996. Protein misfolding and inclusion body formation in recombinant 
Escherichia coli cells overexpressing Heat-shock proteins. Journal of Biological Chemistry, 271, 
11141-11147. 
Thompson,J.D., Higgins,D.G., Gibson,T.J., 1994. CLUSTAL W: improving the sensitivity of 
progressive multiple sequence alignment through sequence weighting, position-specific gap 
penalties and weight matrix choice. Nucleic Acids Research, 22, 4673-4680. 
 
Timasheff,S.N., 1998. Control of protein stability and reactions by weakly interacting 
cosolvents: The simplicity of the complicated. Advances in Protein Chemistry, 51, 355-432. 
 
Tolia,N.H., Joshua-Tor, L., 2006.  Strategies for protein coexpression in Escherichia coli. Nature 
Methods, 3, 55 - 64. 
 
Tortorella,D., Story,C.M., Huppa,J.B., Wiertz,E.J.H.J., Jones,T.R., Ploegh,H.L., 1998. 
Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in 
redox potential. Journal of Cell Biology, 142, 365–376. 
_____________________________________________________________________References 
 
Page | 86  
 
Trampuz,A., Jereb,M., Muzlovic,I., Prabhu,R., 2003. Critical review: Severe malaria. Critical 
Care, 7 (4), 315–323. 
Triglia,T., Stahl,H.D., Crewther,P.E., Scanlon,D., Brown,G.V., Anders,R.F., Kemp,D.J., 1987. 
The complete sequence of the gene for the knob-associated histidine-rich protein from 
Plasmodium falciparum.  EMBO Journal. 6: 1413-1419. 
 
Tsai,B., Ye,Y., Rapoport,T.A., 2002. Retro-translocation of proteins from the endoplasmic 
reticulum into the cytosol. Nature Reviews Molecular Cell Biology, 3, 246–255. 
 
Tsai,J., Douglas,M.G., 1996. A Conserved HPD Sequence of the J-domain Is Necessary for 
YDJ1 Stimulation of Hsp70 ATPase Activity at a Site Distinct from Substrate Binding. Journal 
of  Biological Chemistry, 271, 9347-9354. 
Tu,B.P., Weissman,J.S., 2004. Oxidative protein folding in eukaryotes. Journal of Cell Biology, 
164, 341-346. 
Tyedmers,J., Lerner,M., Bies,C., Dudek,J., Skowronek,M.H., Haas,I.G., Heim,N., 
Nastainczyk,W., Volkmer,J., Zimmermann,R., 2000. Homologs of the yeast Sec complex 
subunits Sec62p and Sec63p are abundant proteins in dog pancreas microsomes. Proceedings of 
the National Academy of Sciences, 97, 7214-7219. 
 
Ushioda,R., Hoseki,J., Araki,K., Jansen,G., Thomas,D.Y., Nagata,K., 2008. ERdj5 Is Required 
as a Disulfide Reductase for Degradation of Misfolded Proteins in the ER. Science, 321, 569-
572. 
Vincensini,L., Richert,S., Blisnick,T., Van Dorsselaer,A., Leize-Wagner,E., Rabilloud, T., Braun 
Breton,C., 2005. Proteomic analysis identifies novel proteins of the Maurer's clefts, a secretory 
compartment delivering Plasmodium falciparum proteins to the surface of its host cell. 
Molecular & Cellular Proteomics, 4, 582-593.  
 
Vitale,A., Ceriotti,A., Denecke., 1993. The Role of the Endoplasmic Reticulum in Protein 
Synthesis, Modification and Intracellular. Journal of Experimental Botany, 44, 1417-1444. 
 
Walter,S., Buchner,J., 2002. Molecular chaperones--cellular machines for protein folding. 
Angewandte Chemie, International Edition, 41, 1098–1130. 
_____________________________________________________________________References 
 
Page | 87  
 
Walsh,P., Bursac,D., Law,Y.C., Cyr,D., Lithgow,T., 2004. The J-protein family: modulating 
protein assembly, disassembly and translocation. EMBO Reports, 5, 567-571. 
Wang,T.F., Chang,J.H., Wang,C., 1993. Identification of the peptide binding domain of hsc70. 
18-Kilodalton fragment located immediately after ATPase domain is sufficient for high affinity 
binding. Journal of Biological Chemistry, 268, 26049-26051. 
Watanabe,J., 1997. Cloning and characterization of heat shock protein DnaJ homologues from 
Plasmodium falciparum and comparison with ring infected erythrocyte surface antigen1. 
Molecular and Biochemical Parasitology, 88, 253-258. 
White, N., 2004.  Antimalarial drug resistance. Journal of Clinical Investigation, 113, 1084-
1092. 
White,N.J., Looareesuwan,S., Warrell,D.A., 1983. Quinine and quinidine: a comparison of EKG 
effects during the treatment of malaria. Journal of Cardiovascular Pharmacology, 5, 173-175. 
 
Wittung-Stafshede,P., Guidry,J., Horne,B.E., Landry,S.J., 2003. The J-Domain of Hsp40 
Couples ATP Hydrolysis to Substrate Capture in Hsp70. Biochemistry, 42, 4937-4944. 
Woodrow,CJ., Haynes,RK., Krishna,S., 2005. Artemisinins. Postgraduate Medical Journal, 81, 
71-80. 
World Health Organisation. (http://www.who.int/en/) 
(Access 6 February 2012) 
Wu,Y., Li,J., Jin,Z., Fu,Z., Sha,B., 2005. The Crystal Structure of the C-terminal Fragment of 
Yeast Hsp40 Ydj1 Reveals Novel Dimerization Motif for Hsp40. Journal of Molecular Biology, 
346, 1005-1011. 
Yan,W., Frank,CL., Korth,MJ., Sopher,BL., Novoa,I., Ron,D., Katze,M.G., 2002. Control of 
PERK eIF2alpha kinase activity by the endoplasmic reticulum stress-induced molecular 
chaperone P58IPK. Proceedings of the National Academy of Sciences of the United States of 
America, 99,15920-15925. 
Yu,M., Haslam,R.H., Haslam,D.B., 2000. HEDJ, an Hsp40 cochaperone localized to the 
endoplasmic reticulum of human cells. Journal of Biological Chemistry, 275, 24984-24992. 
 
 
_____________________________________________________________________References 
 
Page | 88  
 
Zahedi,RP., Volzing,C., Schmitt,A., Frien,M., Jung,M., Dudek,J., Wortelkamp,S., Sickmann,A., 
Zimmermann,R., 2009. Analysis of the membrane proteome of canine pancreatic rough 
microsomes identifies a novel Hsp40, termed ERj7. Proteomics, 9, 3463-3473. 
Zoller,M.J., 1991. New molecular biology methods for protein engineering. Current Opinion in 
Biotechnology, 2, 526–531. 
Zuccala,E.S., Baum,J., 2011. Cytoskeletal and membrane remodelling during malaria parasite 
invasion of the human erythrocyte. British Journal of Haematology, 154, 680-689. 
 
